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Head and Neck Squamous Cell Carcinoma (HNSCC) represents the sixth most common cancer 
worldwide, with about 550,000 new cases/year. 
Despite the development of precise and accurate surgery followed by radio- and/or chemo-therapy, 
in the last decade patients’ overall survival was only slightly improved. In particular, only 40-50% of 
patients with advanced HNSCC will survive for 5 years. The main worse prognostic event is 
considered the onset of loco-regional and distant recurrences, that is also accepted as surrogate 
markers of patients’ overall survival. HNSCC is a heterogeneous disease and, although many studies 
have been conducted to clarify the molecular mechanisms behind the development of local or distant 
metastasis, no clear molecular mediators of recurrence formation have been identified and no valid 
biomarkers exist to identify and treat patients at high-risk of recurrence.  
We aimed to fill this gap taking advantage of an unbiased approach in which we evaluated microRNA 
(miRNA) expression profile in a cohort of HNSCC primary tumours from recurrent and non-recurrent 
patients. 
We identified and validated a four-miRNA signature, composed by miR-1, miR-9, miR-133a and 
miR-150 that could be used as biomarker of recurrence. All these miRNAs are not only well-known 
molecular modulators of cell plasticity in different tumours, but intriguingly in our HNSCC model 
they are also able to classify HNSCC patients at high- or low-risk of recurrence formation.  
We demonstrated that these miRNAs collectively impinge on the epithelial-mesenchymal transition 
process. In silico and wet lab approaches showed that miR-9, expressed at high levels in recurrent 
HNSCC, targets the epithelial genes SASH1 and KRT13, while miR-1, miR-133a and miR-150, 
expressed at low levels in recurrent HNSCC, collectively target SP1 and TGFb pathways.  
In vivo, a six-genes signature comprising the above targets, consistently predicts low progression 
free- and overall-survival in different panels of HNSCC samples. This is of particular clinical 
relevance, since the detection of this gene signature in tumours specimens could identify patients with 
poor prognosis who may benefit for a more accurate targeted therapy. 
In a preclinical model of HNSCC recurrence, the combined pharmacological inhibition of SP1 and 
TGFb pathways, when timely administered, induced HNSCC cell death and prevented recurrence 
formation. 
By integrating different experimental approaches, we identified critical mediators of recurrence 
formation in advanced HNSCC. Since both SP1 and TGFb pathways could be pharmacologically 
targeted, their combined inhibition may merit to be considered for future clinical development. 
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1.1 Head and Neck Squamous Cell Carcinoma 
 
Head and Neck Squamous Cell Carcinoma (HNSCC) originates from the mucosal epithelia of the 
upper aero-digestive tract and encompasses a variety of solid tumours originating in the squamous 
epithelium of lip, oral cavity, hypopharynx, oropharynx, nasopharynx and larynx1. HNSCC 
represents the sixth most common cancer worldwide, with about 550,000 new cases/year worldwide, 
and only the 40-50% of patients will survive for 5 years2. 
HNSCC can be stratified in HPV-negative or HPV-positive malignancies on the basis of the 
etiological factor(s), this is of extremely clinical importance since these two subclasses differ not only 
for pathological and molecular features, but also for the clinical outcome3. 
HPV-negative cluster comprehends the 80% of HNSCCs and are generally more frequent in the adult 
(>60 years) male population. The most important risk factors so far identified are tobacco use and 
alcohol consumption, which seem to have synergistic effect. In the western world, the incidence of 
this subgroup of HNSCC has been slowly declining during the last years, which can be attributed to 
a decrease in the prevalence of risk factors, most notably smoking1,2.  
HPV-positive carcinoma, the minor subclass of HNSCC for incidence, is caused by Human Papilloma 
Virus (HPV) infection and is frequently associated with high-risk sexual behaviours. This subgroup 
affects in prevalence tongue and oropharynx and has the same frequency in men and women, with an 
insurgence usually under 60 years4. 
Even if the 95% of head and neck neoplasia are squamous cell carcinoma, recent insights have 
revealed that HNSCC is unexpectedly heterogeneous. It has been demonstrated that among HPV-
negative early lesions there is a marked inter and intra-tumour genomic variability. 
In this context, TP53 mutations are the most frequent genetic alteration, detectable in more than 60-
80% of HPV-negative HNSCC and playing an uncontested role in the HNSCC pathogenesis, even 
though it could not be considered a univocal prognostic marker5. Many efforts were made in order to 
validate other genetic alteration that correlate with a poor prognosis. Among these mutations, 
CCND1, EGFR and MET amplifications are considered frequent events in early lesions, as well as 
inactivation of important oncosuppressor genes, such as CDKN2A, RB1 and PTEN6. In the late stages 
of HPV-negative diseases, it has been demonstrated increased alterations in pathways belonging to 
E-Cadherin, VEGF, PDGF and more importantly TGFb signalling, contributing to a worst 
prognosis3,7. 
As regarding HPV-positive lesions, there is no correlation neither with TP53 mutations, since they 
are almost all TP53 wild type, or with other risk factors above mentioned. These malignancies are 
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usually less heterogenic and display a particular favourable prognosis respect to HPV-negative 
subclass. 
HPV is the pathogenic agent and the viral genome has been observed in about 72% of the cases. The 
most frequent HPV serotype is HPV-16, which encode E6 and E7 proteins that are able to bind 
respectively p53 and Rb proteins, inhibiting their oncosuppressor functions with dramatic 
perturbation of cell cycle in the infected cells8 (Figure 1).  
 
 
Figure 1. Cell Cycle dysregulation by HPV infection.  
This schematic representation of cell cycle principal effectors shows, in red bars, the G1/S and the G2/M 
checkpoints. These two important steps are mainly controlled by RB pocket proteins and p53 respectively. RB 
proteins normally bind to and inactivate E2Fs transcription factors, which induce the expression of S phase 
genes. The key protein p53, once activated by phosphorylation, acts as a stress-induced transcription factor 
leading to p21CIP expression which in turn inhibits several cyclin-CDK complexes to cause cell cycle arrest. 
HPV genome contains various early and late open reading frames and encodes two viral onco-proteins: E6 and 
E7. The E6 protein binds p53 and targets the protein for degradation, whereas the E7 protein binds to inactivate 
RB pocket proteins. The molecular consequences of these viral onco-proteins expression are cell cycle entry 
and inhibition of p53-mediated apoptosis, which allows the virus to replicate. In a “oncogenic infection”, the 
expression of E6 and E7 is not confined to the differentiating layer of the squamous epithelium, but it is 
detectable also the basal layer, where stem cells reside, and causes abrogation of the cell cycle checkpoints 
and virions production. Figure has been adapted from “The Molecular Biology of Head and Neck Cancer”, 
Leemans et al9. 
 
The prognosis of HNSCC patients is largely determined by the stage at presentation, which 
comprehends an evaluation of the extent of the tumour, as well as the presence of lymph-node 
invasion and distant metastases. The tumour stage of HNSCC is defined by clinical examination, with 
the integration of different disciplines, including imaging, cytology of lymph-nodes and tumour 
histopathology after surgery (such as radicality and extra-nodal spread)9.  
Recently, HPV status and tobacco use have also been shown to be of significant prognostic 
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importance, possibly outweighing the traditional tumour, node, metastasis (TNM) staging system in 
oropharyngeal tumours4.  
Early-stage tumours (stage I/II), representing the minor part of the cases, are treated with surgery or 
radiotherapy alone and have a favourable prognosis. The mainstays of treatment for advanced 
tumours (stage III/IV) are surgery combined with postoperative chemo and/or radiotherapy10.  
The standard chemotherapy for advanced patients (stage III or IV) is the administration of Cisplatin, 
as radio-sensitizing agent, 100 mg/m2 once every three weeks11,12. To overcome the frequent and 
highly toxic side effects, this schedule could be adapted to a decreased dose administrated once a 
week, or preferring the use of Carboplatin or Paclitaxel13. 
A recent meta-analysis demonstrated that the combination of chemo- and radio-therapy is a valid, 
although highly toxic, therapeutic option and despite this aggressive schedule, the 5-year survival of 
HNSCC patients ranges from 35 to 55% and has not markedly improved in recent decades, mostly 
due to the aggressive and invasive growth pattern as well as high resistance against available 
therapies, leading to loco-regional relapse and/or distant metastasis13.  
As mentioned before, independently from the etiological agents, HNSCC is relative heterogeneous 
disease and its progression is a stepwise process, resulting from the accumulation of molecular 
alterations in the squamous epithelium, which eventually drive the progression from premalignant 
lesions to invasive disease14,15 (Figure 2).  
The limited information available on the molecular carcinogenesis of HNSCC, and the genetic and 
biological heterogeneity of the disease has hampered the development of new therapeutic strategies. 
While inactivation of p53 and RB pathways are considered an early, nearly universal event in HNSCC 
progression, either through somatic mutation/inactivation of critical tumour suppressor genes (e.g. 
TP53 and CDKN1A) or through HPV infection, less is known about the subsequent molecular events 
necessary for the progression of HNSCC to invasive, metastatic carcinomas16,17.  
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Figure 2. Schematic representation of molecular carcinogenesis of HNSCC.  
A progenitor or adult cell in the normal mucosa acquire one (or more) genetic alteration, including TP53, either 
by mutation (HPV-negative) or by inhibition (HPV-positive). This mutated cell forms a patch containing 
genetically altered daughter cells, without proper growth control, that develops an expanding field. Successive 
and eventual transforming events or the accumulation of other mutations turn the field to an overt carcinoma, 
displaying invasive growth and metastasis capabilities. Figure has been adapted from “The Molecular Biology 
of Head and Neck Cancer”, Leemans et al9. 
 
Recently, it has been demonstrated that in about 90% of HNSCC early lesions an overexpression of 
EGFR could be detected by IHC18. This observation, together with the notion that a positive 
regulatory loop exists between EGFR and Cyclin D1 transcription19, supported the hypothesis to 
develop new therapeutic strategies involving the combined treatment with targeted- and standard 
chemo- or chemo/radio-radiotherapy17,20. In this context, several studies have been conducted to 
validate the efficacy of Cetuximab, a chimeric immunoglobulin which selectively targets an epitope 
of the EGFR ligand-binding domain, combined with radio or radio/chemo-therapy in advanced 
HNSCC21,22. A phase III multicenter trial randomized showed encouraging results comparing the 
efficacy of definitive radiotherapy and radiotherapy plus Cetuximab. In this trial, the administration 
of Cetuximab 400 mg/m2 loading dose followed by 250 mg/m2 weekly for 8 planned doses, designed 
to overlap the planned ~7 weeks of radiotherapy or 7 weeks of radiotherapy alone, demonstrated a 
significant improvement for the addition of Cetuximab23. 
Although the toxicity of Cetuximab does not overlap with those of Cisplatin, the addition of 
Cetuximab to standard radio/chemo-therapy did not exert expected results, possibly due to the 
exacerbation of side effects in advanced HNSCC patients24. 
This observation, together with the remarkably pathway alteration and genomic heterogeneity of 
HNSCC, implies that identifying patients that will recur could be extremely beneficial for the 
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management of HNSCC patients, to avoid unnecessary toxicity and improve patients’ survival. To 
date no validated biomarkers exist to identify HNSCC patients with higher probability to develop 
recurrences and that, therefore, may merit a closer follow-up or different therapeutic approaches. 
 
1.2 Epithelial To Mesenchymal Transition 
 
Epithelial-to-Mesenchymal Transition (EMT) is a complex physiological process in which 
differentiated epithelial cells lose their characteristic features and acquire a mesenchymal-like 
phenotype. Typical phenotypic hallmarks of EMT are the loss of cell-cell junctions, loss of apical-
basal polarity and acquisition of migratory and/or invasive properties. The contrary process, defined 
as Mesenchymal-to-Epithelial Transition (MET), is characterized by the loss of these migratory and 
invasive features and the acquisition of an organized cell polarity25.  
These two transitions, that recapitulate the concept of cell plasticity, and their dynamic phenotypes 
resemble fundamental processes during embryonic development and wound healing26–28.  
Many studies identified as “master EMT-regulators” a large range of developmental and growth 
factor signals (principally TGFb, Notch1, Wnt, EGF, HGF, FGF and IGF) able to drive EMT by 
triggering genetic and epigenetic programs (i.e. post-transcriptional control, alternative splicing, 
protein stabilization and/or localization), which are controlled by or regulate a specific core set of 
transcription factors (EMT-TF) belonging to different families, including SNAI1/2, TWIST1, and 
ZEB1/2, among others (Figure 3)28–30. 
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Figure 3. Schematic representation of epithelial cell plasticity.  
The diagram shows the main events occurring during the switch from epithelial into mesenchymal cells. As 
mentioned, several events and effectors influence each other during the progression of EMT and viceversa 
MET process. Figure has been adapted from “Complex networks orchestrate epithelial-mesenchymal 
transitions”, Thiery and Sleeman31. 
 
The mechanism is the result of sophisticate interactions between microenvironment and EMT-
associated pathways whose orchestrate, through direct or indirect interactions in a tissue and cell-
specific manner, the modulation of cell plasticity25,32. This in turn regulates many hallmarks of cancer, 
such as apoptosis, cell-cycle, metabolism and, more recently, EMT has been proposed also as an 
escape strategy mediating also chemo- or radio-resistance. Nevertheless, emerging evidence suggests 
that EMT is fundamental to gaining “stemness” feature or the transition of neoplastic cells to 
becoming cancer stem cells (CSCs), that as a fountainhead for tumours, could sustain the remaining 
population of tumour cells, and eventually contribute to treatment resistance33–35.  
For this reason, in the last decade, EMT has becoming of increased pathophysiologic interest, since 
cancer cells are able to reactivate the EMT program to gain new and more aggressive properties.  
In the past, most studies relied on morphological alterations complemented by the detection of 
epithelial (i.e., E-cadherin) and mesenchymal markers (i.e., vimentin, fibronectin, N-cadherin) to 
assess an epithelial or a mesenchymal state as a simple binary decision30,36–38. However, more recent 
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evidence has advanced and broadened the definition of EMT as a program with dynamic transitional 
states characterized by metastable intermediates, a sort of hybrid neoplastic cells39. This concept is in 
line with the high degree of tumour cell plasticity, which has been described for most tumour entities 
(including HNSCC), and might be the main driver of intrinsic or acquired resistance to established 
treatment regimens like platinum-based chemotherapy or radiation40.  
Epithelial plasticity and mesenchymal conversion is often seen in cancer cells as they leave the 
primary tumour and disseminate to other parts of the body to colonize distant organs and form 
metastases, which is responsible for the vast majority of cancer-related deaths. However, EMT-
related invasion in combination with tumour cell dissemination is initiating, but is not sufficient for 
completion of the metastatic cascade. For metastatic colonization, the reversal MET is necessary to 
support tumour cell expansion, an important prerequisite for metastatic growth. In this context, hybrid 
epithelial/mesenchymal cells are able to detach from the primary tumours as a cluster and maintain 
the migratory and invasive features to give rise to the metastatic cascade. In contrast to EMT, 
extracellular signals or cell intrinsic programs involved in the induction of MET have not been well 
characterized. It is also worth noting that tumour cell dissemination and metastatic colonization does 
not exclusively rely on changes in cell identity related to the EMT program and its reversal, and other 
scenarios are also reasonable32,39.  
In cancer research, EMT mechanism represents an important clinical challenge for the peculiar 
aggressiveness acquired by cancer cells, in term of relapse potential, distant dissemination and 
chemio/radio-resistance33,40. There are many studies which addressed the possibility to validated 
EMT-regulators as possible therapeutic targets or prognostic markers, but no satisfactory results have 
been obtained mainly because of the intrinsic heterogeneity of tumour cells and microenvironment. 
As an example, in the same tumour mass a kaleidoscopic range of different epithelial/mesenchymal 
phenotypes can be distinguished, not only for gene expression profile, but also for cell localization: 
the external neoplastic cells tend to express classical mesenchymal markers, as detectable from N-
Cadherin or ZEB1, whereas the inner tumour cells express typical epithelial marker, such as E-
cadherin and cells with hybrid phenotypes arrange in the middle part of the tumour mass, as result of 
their EMT-MET balance41.  
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1.3 TGF-β pathway in HNSCC 
 
TGF-β, as bioactive dimer, brings together TGF-β receptor I and II (TGFBR-I and TGFBR-II). On 
binding TGF-β, the type II receptor phosphorylates and activates TGFBR-I, that then propagate the 
signals by phosphorylating the SMADs 2 and 3 proteins. This activated complex recruits SMAD4 to 
translocate into the nucleus. The SMAD2/3-SMAD4 complex together with other adaptive proteins 
and cofactors, is able to bind with high affinity and specificity several selected target genes to enhance 
their transcription42.  
SMAD2/3/4 complex is very suitable for many interactions, this observation introduces the high 
pleiotropy of TGF-β functions, closely dependent also from the context (microenvironment, tissue, 
cell type) (Figure 4). 
 
 
Figure 4. Depiction of TGF-β signalling pathway.  
The canonical TGF-β signalling relayed to SMADs pathway seems to play the most important role in HNSCC. 
This observation reflects the frequent down-modulations of TGFBR-II and SMAD4 described in HNSCC that 
enable neoplastic cell to respond to the anti-proliferative signals activated by TGF-β cascade. Figure has been 
adapted from “The Molecular Biology of Head and Neck Cancer”, Leemans et al9 
 
TGF-β is an important paracrine cytokine that has both growth-promoting and -suppressive effects 
on cells. Typically, it regulates diverse cellular activities such as inhibition of mitosis, proliferation 
and cell survival or promotion of differentiation and apoptosis. It is deeply involved in neural 
development, maintenance of immune surveillance and wound healing process.  
Nowadays, its controversial role is under investigation, since it is well understood that acts as a 
tumour-suppressor in early tumorigenesis, and becomes an enhancer of malignant phenotype in 
advanced phases. Deregulation of TGF-β pathway in malignancy occurs through several mechanisms, 
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including loss of response to its ligand, defects in the transduction pathway, and others42–44. In 
particular, HNSCC has been shown to be resistant to the suppressive effects of TGF-β, through a 
frequent down-modulation of TGFBR-II or SMAD4, which elicits for lethal TGF-β-driven EMT and 
correlates with a poor prognosis45–48. 
Intriguingly, TGF-β as primary factor triggering EMT, is able to activate, as well as other 
inflammatory cytokines such as TNF-α or IL-6, STAT3 signalling which converge in the activation 
of diverse EMT-associated transcription factor: Twist, Snail, and Slug (Snail2), that exacerbate the 
EMT phenotype, not only in HNSCC29,35.  
As mentioned above, although EMT is of potential clinical impact, the pharmaceutical inhibition of 
“master EMT regulators” presents some grave limitations: considering the TGF-β pathway in 
pancreatic cancer, the abrogation of its signalling limits its pro-apoptotic function and nevertheless 
the EMT inhibition, depending on cell type, could also revert the phenotype of hybrid tumour cells, 
leading to a reverse MET, able to establish an epithelial cell expansion and subsequent metastasis 
formation49. In this scenario, the major biological challenge is to defined and identify EMT-evolution 
markers and translate them into the clinical practice, since advanced HNSCC patients, stratified for 
tumour isotype, could benefit for a timely administration of EMT-targeted therapy.  
As regard to locally advanced HNSCC, different studies have demonstrated a strong and frequent 
alteration of the TGF-β pathway and demonstrated its pivotal and controversial role in the 
establishment of an EMT phenotype, with dramatic consequence concerning recurrence and/or 
metastasis formation in HNSCC45–47.  
 
1.4 microRNA in HNSCC 
 
microRNA (miRNAs) are small non-coding RNA molecules (17-25 nucleotides) that regulate post-
transcriptional gene expression by relatively non-specific binding to the 3'-untranslated region (3’-
UTR) of target mRNA50. Their biogenesis has been clarified and seems to be more complex than 
other genes. miRNAs sequences are located within various genomic context: the majority of 
canonical miRNAs are encoded by introns of non-coding or coding transcripts, and also by exon 
regions. Some miRNA genes reside in the introns of protein-coding genes and, thus, share the 
promoter of the host gene. However, it has been noted that miRNA genes often have multiple 
transcription start sites and that the promoter of intronic miRNAs are sometimes distinct from the 
promoter of their host gene51. The transcription of primary miRNA (pri-miRNA) is carried out by 
RNA-polymerase-II, and its associated co-factors, that leads to the formation of about 1 kb pri-
miRNA, containing different stem-loop sequence in which the mature miRNA sequence is 
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embedded52. Following the transcription, the first step of miRNA maturation is initiated by nuclear 
RNA-III, Drosha. This enzyme crops the stem-loop to release a small hairpin-shaped RNA of about 
65-75 nucleotides in length (pre-miRNA)53. Following the cleavage, pre-miRNA is exported into the 
cytoplasm by Exportin 5 (EXP5), where the maturation can be completed. Once in the cytosol, pre-
miRNA is cleaved by Dicer, that release a small double strand RNA (dsRNA)54. This small RNA 
duplex is loaded onto AGO protein to form an effector complex, named RNA-induced silencing 
complex (RISC), that rapidly remove the passenger strand releasing the mature single strand 
miRNA55–57 (Figure 5). 
 
 
 
Figure 5. microRNA biogenesis pathway. Schematic representation of miRNA biogenesis with the principal 
effectors of transcription and maturation processes. The complex regulation of miRNA expression is perturbed 
in almost all biogenesis step (as indicated with the red arrows) by genetic, and more frequently, epigenetic 
factors. Figure has been adapted from “miRNA Dysregulation in Breast Cancer” Mulrane et al58. 
 
The imperfect base-pairing between a single miRNA and the target mRNA leads to a potential and 
dynamic regulation of several gene expression. It has been proposed that miRNAs regulate 
approximately 30% of human genes59.  
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It has been demonstrated that miRNAs are specifically express in diverse tissue and biological fluids, 
and particular miRNAs pattern are characteristic of different cell type and function. Moreover, they 
are involved in essential biological activities and cellular processes, including the regulation of cell 
cycle, proliferation, differentiation, development and apoptosis60.  
Due to their pleiotropic features and the amount of essential cell activities in which they are involved, 
it is not surprising that an unbalanced miRNA expression could play a role in cell plasticity and cancer 
development. 
In this context, the interesting in the exploration of miRNA expression and their role in the molecular 
biology of human diseases has increased in last decades. The relative easy detection of miRNAs in 
different tissue and biological fluids has led to intensive investigations with innovative technologies 
with the aim to identify specific biomarkers, useful in characterizing cancers biology and discovering 
novel therapeutic targets61,62. 
Since, cancer cell plasticity is regulated epigenetically, it has been hypothesized that the regulation 
of miRNAs could play a primary role also in HNSCC cell plasticity63. 
After the seminal demonstration that a reciprocal feedback loop exists between the miRNA-200 
family and the ZEB transcription factors to tightly control EMT, the number of miRNAs that has 
been directly or indirectly associated with EMT is becoming an extensive list64.  
The role of miRNA expression in HNSCC has been widely investigated and several differentially 
expressed miRNAs in normal/peritumoural mucosa versus primary tumours have been identified. 
However, no study has specifically compared the expression profile of miRNAs in primary tumours 
from patients who have recurred versus patients that have not65–67.  
To further improve patient outcomes with more effective therapeutic approach, we investigate and 
identify a 4-miRNAs signature able to identify HNSCC patients at high risk of recurrence and 
describe the mechanism whereby they orchestrate the expression of genes regulating cancer cell 
plasticity via EMT modulation.  
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Head and Neck Squamous Cell Carcinoma represents the sixth most common cancer worldwide, with 
about 550,000 new cases/year. Independently from the etiological risk factor(s), HNSCC is an 
unexpected heterogeneous disease, possibly due to the accumulation in genetic mutation occurring 
during the tumour staging.  
Most patients are diagnosed with a locally advanced disease and are treated with surgery in 
combination with radiotherapy and/or chemotherapy. This highly toxic schedule is curative only in 
about half of the cases, and despite this aggressive treatment about 40-50% of patients will survive 
for 5 years. On one side, for advanced HNSCC patients, surgery alone is not sufficient for the whole 
excision of tumour mass mainly due to the invasive burden close to physiological complex structure 
for which the maintenance of functionality is mandatory and this allows the growth of residual tumour 
cells and their local or distant invasion. On the other side the combined addiction of radio- or 
chemotherapy is not well tolerated due to the grave side effects, and for this reason, in many cases, 
the effective dose could be decreased and adapted to each patient, leading to a high percentage of 
resistance to standard therapy.  
The development of local or distant recurrences remains the major clinical challenge, since recurrent 
patients do not have effective salvage therapies. Therefore, there is the urgency to identify and 
validate solid biomarkers able to classify patients at high risk that may benefit for specific targeted 
approaches. This PhD project tackled these two unmet clinical needs and aimed to identify a 
microRNAs signature of loco-regional recurrence in patients with HNSCC.  
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3.1 Patient samples 
Specimens from primary HNSCC were collected from patients who underwent surgery at our 
institution and at Santa Maria degli Angeli Hospital, Pordenone, Italy. HNSCC specimens were 
immediately frozen and stored at -80°C. The study was approved by the Internal Review Board of 
the Centro di Riferimento Oncologico (CRO) of Aviano (#IRB-08/2013) and all patients provided 
written informed consent.  
 
3.2 Bioinformatic analyses 
 
Computational analysis includes two parts: A) Uni-Variant Statistical Significance Testing of 
miRNA-1, miRNA-9, miRNA-133a, and miRNA-150 (one miRNA at a time)68. B) Testing Sample 
Classification based on molecular signatures using models constructed from combinations of 
miRNAs. More specifically, we test the above 4 miRNAs together, and every combination of 2 or 3 
miRNAs listed above69,70.  
 
3.2.1 Uni-variant Significance Test by The Permutation Test 
This established test was used to calculate the statistical significance of each of the four miRNAs 
(miRNA-1, miRNA-9, miRNA-133a, and miRNA-150) individually. A low p-value for the miRNA 
indicates higher confidence in how well it separates recurrence from non-recurrence patients. For 
this, we used the permutation test to estimate the p-values for each miRNA. The permutation test 
works by first measuring the observed difference between the two patient groups (recurrence vs. non-
recurrence) for the given gene, then, it randomly shuffles the samples across the two groups k times 
and it counts how often it encounters a difference greater or equal to the observed difference. When 
K is large (we used 10000000), the p-value is the ratio between how often a difference greater or 
equal to the observed difference is measured randomly (due to chance) out of K. The permutation test 
is advantageous because it is parametric, it makes no assumptions, and it can be used with small 
sample size.  
 
3.2.2 Testing of Sample Classification  
This second test was used to build and test a computational prediction model that predicts recurrence 
based on the miRNAs expressions. However, the accuracy of prediction relies on the process of 
classifier construction. In this process, we address challenges mentioned earlier to improve prediction 
accuracy. Therefore, we adopt the under-sampling technique described by W. Klement et al70, to 
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counter the effects of class imbalance and the potential over-fitting. The idea is based on selecting 
equal portions from both patient groups used to train the classifier. For illustration, if the training data 
has 9 recurrence cases and 29 non-recurrence cases, we select all 9 recurrence cases, plus randomly 
selected (without replacement) 9 non-recurrence cases to a total of 18 cases for use in training the 
classifier. In other words, the under-sampling policy is to include the entire minority class cases and 
randomly subsample an equal proportion of cases in the majority class. This process is then repeated 
and the average performance is determined. The repeated training and testing demonstrates the 
reliability and robustness of predictions. For method of classification, we report our results using two 
very different methods: Naïve Bayes and Logistic Regression methods. While the former is a simple 
probabilistic classifier based on applying Bayes' theorem, the latter constructs a regression model for 
binary classification. Classifier testing policy is based on repeated 10-fold cross-validation. This 
strategy follows: we first partition the data randomly into 10 stratified folds. The stratification ensures 
that every fold i of the 10 folds has approximately the same proportions of positive (recurrence) 
samples and negative (non-recurrence) samples. For every fold i, we use the remaining 9 folds for 
training a classifier, and then, we test the resulting classifier on samples in fold i. This process is 
repeated for all 10 folds to produce predictions for all samples. Then, we calculate the performance 
metrics for evaluation (they are described below). This entire testing strategy (starting with the 
random data partitioning) is repeated 10000 times and the average and standard deviations are 
calculated. The reason for the repetitions is to eliminate the potential systematic overlap of 8 folds in 
testing two consecutive folds, a consequence of 10-fold cross validation strategy. 
 
3.2.3 Network analysis 
After downloading predicted miRNA–gene interactions for the genes in our network from the 
miRNADIP portal ver. 1 (http://ophid.utoronto.ca/mirDIP)71, which integrates 12 microRNA 
prediction datasets, we kept only those interactions that were identified in at least three independent 
datasets.  We then integrated the analysis using genes up- or down-regulated in head neck recurrences 
from CDIP, the Cancer Data Integration Portal ver. 1 (http://ophid.utoronto.ca/cdip), a collection of 
gene expression data from published studies. We also used a list of genes associated with recurrence 
formation in HNSCC from a published cohort72.  
Next, we uploaded this list of gene IDs into NAViGaTOR 3 as our network visualization tool 
(http://ophid.utoronto.ca/navigator)73 and retrieved known, publicly available human physical protein 
interaction using the I2D 2.2 portal (http://ophid.utoronto.ca/i2d)74. Our goal was to explore the 
relationships between our 4 miRNAs and genes known to regulate recurrence formation in HNSCC. 
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Network nodes represent miRNAs and proteins respectively, while edges represent physical protein-
protein interactions (PPIs) and microRNA:gene regulation. We downloaded the list of the 4 miRNAs 
targets from the miRNADIP database ver. 1 (http://ophid.utoronto.ca/miRNADIP/) and then we 
looked at the intersection among genes that control recurrence formation, genes associated to a pro-
survival signature and the 4 miRNAs targets72. 
3.2.4 PathDIP analyses 
We analyzed 56 genes, involved in recurrence formation72, as potential miRNA-9 targets. These 
pathway analyses were conducted using pathDIP Ver. 2.4.3.12 (http://ophid.utoronto.ca/pathDIP)75. 
3.2.5 Analysis of the TCGA dataset 
Correlation analysis using HNSCC TCGA RNAseq and microRNA-seq data for SASH1, KRT13 and 
hsa-miRNA-9 were performed using Spearman correlation76. All statistical analyses were performed 
using [R] (https://www.r-project.org/). KRT13/SASH1 correlation analysis using HNSCC TCGA 
RNAseq data were performed using cBioPortal for Cancer Genomics (http://www.cbioportal.org/)77.  
Clustering of RNAseq values was performed using Ward linkage. This approach identified cluster 1 
with high expression of KRT13/SASH1 and low expression of TGFβR1/2, SMAD3 and SP1, while 
cluster 2 is characterized by high expression of TGFβR1/2, SMAD3, SP1 and low expression of 
SASH1/KRT13. The associations of the 2 clusters with survival was evaluated with the log-rank test 
using the survival package in R. HNSCC TCGA patients were stratified either by high mRNA 
expression of KRT13/SASH1 and low SMAD3 (above median of mRNA expression, below median 
of mRNA expression, respectively) or by high mRNA expression of SMAD3 and low mRNA 
expression of KRT13/SASH1. Cox proportional hazards regression analysis based on the KMsurv 
package in R was used to assess the hazard ratios. All HNSCC TCGA data were downloaded using 
the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) and the cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/) 
To validate prognostic properties of the four-miRNA signature, we used SurvMicro v.0.9 
(http://bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.jsp)78. Signature was validated on 
TCGA LUAD Ilumina HiSeq dataset, comprising 311 patient samples. All settings were used as 
default.  
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3.3 Cell Biology Experiments 
3.3.1 Cell culture 
FaDu, Cal27, UMSCC1 and UMSCC74b cells were cultured in Dulbecco modified Eagle medium 
(DMEM, Sigma) supplemented with 10% fetal bovine serum (FBS, Gibco). SCC9, SCC15 and 
SCC25 cells were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium (Sigma) and 
Ham's F12 medium (Sigma) containing 1.2 g/L sodium bicarbonate (Sigma), 2.5 mM L-glutamine 
(Sigma), 15 mM HEPES (Sigma) and 0.5 mM sodium pyruvate (Sigma) supplemented with 400 
ng/ml hydrocortisone (Sigma) and FBS 10%. All cell lines were authenticated by BMR Genomics srl 
Padova, Italia, according to Cell ID TM System (Promega, USA) protocol and using Genemapper ID 
Ver 3.2.1, to identify DNA STR profiles. UMSCC74b and UMSCC1 cells were kindly provided by 
Dr. Thomas Carey (University of Michigan, Ann Arbor, MI). All other head and neck squamous cell 
lines were obtained from ATCC (LGC Standards).  
All in vitro studies were performed in triplicate, unless otherwise specified.  
 
3.3.2. Lentiviral trasduction of FaDu and SCC9.  
FaDu and SCC9 cells were transduced with Lentiviruses expressing anti-miRNA-9-5p (MISSION® 
Lenti miRNANA inhibitor human has-miRNA-9-5p, HLTUD0946, Sigma) according to the 
manufacturer protocol. Cells were transduced with anti-miRNA-9 (or control) lentivirus and selected 
in 1.0-1.5 µg/ml puromycin. 
 
3.3.3 miRNA-mimic or inhibitor transfection. 
 Anti-miRNA-9 (MISSION® Synthetic miRNA inhibitor Sigma) were used to transiently 
knockdown miRNA-9 in FaDu and SCC9 cells. Hsa-miRNA-1, -133a, -150 (mission® miRNA 
mimic) were used to overexpress alone or in combination these microRNAs. miRNA inhibitor, mimic 
or control were transfected into different HNSCC cells using Oligofectamine Transfection Reagent 
(LifeTechnologies) according to manufacturer protocol. 
 
3.3.4 Cell viability and IC50 drugs calculation.  
HNSCC cells were seeded in 96-well culture plates (2-4x103 cells/well) and after 24 hours treated 
with increasing doses of the different drug (MTA, SB43, SB52, Erlotinib, Gefitinib and Cetuximab) 
for 72 hours. Combination treatments using MTA plus SB52 or SB43 were performed as above using 
MTA at the IC50 concentration, calculated for each cell line, and increasing doses of SB52 or SB43 
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for 72 hours of treatment. Cell viability was determined at the end of treatment using the 
CellTiter96AQueous cell proliferation assay kit (Promega).   
For CDDP treatments, FaDu or SCC9 control or stably expressing antimiR-9 cells were plated as 
above and treated with increasing dose of CDDP for 16 hours. Cell viability was determined as above 
24 hours after the end of the treatment. 
 
3.3.5 Luciferase assay.  
Luciferase assay was used to validate miRNA-9, miRNA-1, miRNA-133a and miRNA-150 putative 
target sites on SP1 and SASH1 3’ UTR. We amplified sequences surrounding the putative miRNA-
1, -133a, -150 and -9 binding sites from FaDu cells genomic DNA using specific primers carrying 
restriction endonuclease sequence XbaI. PCR products were cloned in pGL3 control vector 
(Promega) digested with XbaI (Promega), at the 3’ of the luciferase gene, which is under the 
regulation of SV40 promoter. Primers used to amplify SASH1 and SP1 sequences are reported below: 
 
 
 
 
Primer Sequence 5’- 3’ 
GeneBank 
Accession 
3’ UTR SASH1 A FW TCTAGATGGACAAGAGCCACCCTTTC NM_015278 
3’ UTR SASH1 A Rev TCTAGAAGACAGAAGAGCAAGGGCAC NM_015278 
3’ UTR SASH1 B FW TCTAGATGGCTGCGAATGCTCTATCT NM_015278 
3’ UTR SASH1 B Rev TCTAGACTGGTCGAGCCAGATGTTCTA NM_015278 
3’ UTR SASH1 C FW TCTAGATGTTTTACAACTGATTTCAGCACA NM_015278 
3’ UTR SASH1 C Rev TCTAGATCAAGGGCTTGTGGTCAAGG NM_015278 
3’ UTR SP1 A FW TCTAGATTCTCTTCTCAGCTCTTCCATGA NM_138473 
3’ UTR SP1 A Rev TCTAGAAGTCGAAGAAGCTGATCCCAA NM_138473 
3’ UTR SP1 B FW TCTAGAGTTCTTGGGTGGTTCCTAAGGG NM_138473 
3’ UTR SP1 B Rev TCTAGAACAATGCTTTTATGGCTGGGC NM_138473 
3’ UTR SP1 C FW TCTAGATGCTGGTTTACCCTCAACCC NM_138473 
3’ UTR SP1 C Rev TCTAGACTGCCCTCGAAGTTTTGGTC NM_138473 
3’ UTR SP1 D FW TCTAGACATAGCTCTCCTTCCCCCTCA NM_138473 
3’ UTR SP1 D Rev TCTAGATTGGGAAGGCAGACAAAGAGA NM_138473 
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For the luciferase assays, 293T17, CAL27 or FaDu were co-transfected with 500 ng of the reporter 
construct and 50 ng of pRL-TK vector (internal control) in 24-well plate using FuGENE® HD 
Transfection Reagent (Promega) according to manufacturer’s recommendations. After transfection 
cell lysates were assayed for luciferase activity using the Dual-Luciferase reporter assay system 
(Promega). Values were normalized using Renilla luciferase. 
 
3.3.6 Irradiation and clonogenic survival assay  
Irradiations were performed using a 137Cs irradiator (Nordion) at a dose rate of ~1 Gy/minute or a 
Clinac 600 C (Varian Medical Systems, Palo Alto, CA) linear accelerator (LINAC) for external beam 
radiation therapy, at ambient oxygen concentrations and in cell adhesion conditions. In the case of 
irradiation with the LINAC, cell plates were positioned at the center of the radiation field of 40 × 40 
cm2 size, with LINAC gantry at 180°, between two 5 cm layers of solid water. The dose delivered to 
cell plates was 2 or 5 Gy at a dose rate of ~ 2.5 Gy/minute, as calculated from measurements with 
radiochromic films in the same setup of irradiation.  
For the clonogenic assay the number of cells to seed was calculated using the following formula:  
 
N° cell = N° optimal counting colonies/plating efficiency in standard conditions/likelihood of 
predicted survival. 
 
Cells were seeded in 6-well plates or 60 mm dishes (two dilutions, in triplicate) and let adhere to the 
plates. Cells were then irradiated and maintained at 37 °C and 5% CO2 for 10-15 days, refreshing the 
medium every 3-4 days. Colonies were then fixed and stained with 1% (w/v) methylene blue in 50% 
ethanol or with 0.5 mg/ml crystal violet in 20% methanol. Colonies with more than approximately 
50 cells were counted manually and clonogenic survival fraction (SF) was expressed as the relative 
plating efficiencies of the irradiated to the control cells. At least three independent experiments were 
performed for every condition. Where indicated, the clonogenic assays were performed without 
radiation treatment. Briefly, cells were seeded in 6-well plates (two dilutions, in triplicate) and let 
adhere. Cells were then incubated for 10–15 days with appropriate culture medium changes every 3-
4 days. Past 10-15 days, growth was blocked and the colonies stained and counted, as described 
above.  
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3.3.7 Anchorage independent soft agar assay 
To evaluate the anchorage-independent cell growth, 1.5x104
 
FaDu or SCC9 control or stably 
transduced with antimiR-9 were re-suspended in 2 ml top agar medium (appropriate cell medium + 
10% FBS, 0.4% Low Melting Agarose, SIGMA) and quickly overlaid on a previously gelified 0.6% 
bottom agar medium (appropriate cell medium + 10% FBS, 0.6% Low Melting Agarose, SIGMA). 
The experiments were performed in six-well tissue culture plates, in triplicate. Fresh medium was 
added to the wells twice a week as a feeder layer. After three weeks, the number of colonies was 
counted in 10 randomly chosen fields, at 10X magnification.  
 
3.3.8 Reagents 
 Mithramycin A (MTA), an aureolic acid compound that specifically inhibits SP1 activity, SB-
525334 (SB52) and SB431542 (SB43), two potent and selective inhibitors of TGFβR1. All 
compounds were purchased from Sigma and used for in vitro and/or in vivo experiments.  
Cisplatin (CDDP) was purchased from TEVA Italia.  
EGFR inhibitors, Gefitinib and Erlotinib, were purchase from Selleck Chemicals, whereas Cetuximab 
(Erbitux) from Merck Serono. 
 
3.4 Molecular Biology Experiments 
 
3.4.1 DNA extraction and evaluation of TP53 mutational status and HPV DNA status  
Total DNA was isolated from patient-derived primary tumors using QIAamp DNA Mini Kit 
(QIAGEN, Germany) according to manufacturer protocol. Total DNA was quantified using 
QuantiFluor® dsDNA System (Promega). 
HPV genotyping was determined in all samples using the INNO-LiPA HPV Genotyping Extra assay 
(Innogenetics, Belgium) and following the manufacturer’s instructions. The INNO-LiPA HPV assay 
is a PCR-based hybridization assay that includes a cocktail of biotinylated consensus primers (SPF 
10) to amplify a 65 bp region within the L1 ORF (open reading frame) of multiple HPV types. After 
DNA extraction, all specimens were subjected to PCR amplification (40 cycles) using the Inno-LiPA 
HPV Genotyping Extra Amp. The PCR product was then denatured, and a 10-µl aliquot was 
hybridized onto nitrocellulose strips where the HPV type-specific oligonucleotides were already 
bound. After 60 min at 49°C, the PCR product bound to a specific probe was detected by an alkaline 
phosphatase-streptavidin conjugate and colorimetric detection.  
TP53 mutational status was assessed by next generation sequencing (NGS) with an amplicon-based 
strategy to cover with at least a 1000X coverage and 5% of sensitivity the whole TP53 sequence. 
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TP53 NGS primer list is available upon request. PCR products were generated using a high fidelity 
Taq polymerase (Phusion High-Fidelity DNA Polymerase; Thermo Scientific, Waltham, MA) and 
subjected to NGS on a MiSeq sequencer (Illumina, San Diego, CA). Data were analyzed with MiSeq 
reporter (Illumina) and IGV software against human genome assembly hg19. Results were expressed 
as percentage of mutated DNA.  
 
3.4.2 RNA extraction and qRT-PCR analyses.  
Total RNA for miRNA microarray and qRT-PCR analyses was isolated from patient-derived primary 
tumors or cell cultures using Trizol solution (Roche Applied Science Mannheim, Germany) according 
to manufacturer protocol. Total RNA was quantified using NanoDrop (Thermo Fisher Scientific Inc., 
USA). MiRNAs expression profile was performed using the Nanostring™ technology (NanoString 
nCounter Human miRNA assay (v1.1) that allowed to evaluate the expression of 746 miRNAs (664 
Human 82 Viral) along with the one of housekeeping genes (GeneBank GSE89000).  
Differentially expressed miRNAs were validated using the TaqMan single tube MicroRNA Assays. 
All reagents, primers and probes were obtained from Applied Biosystems and Reverse Transcriptase 
(RT) reactions and qRT-PCR were performed according to the manufacturer instructions (Applied 
Biosystems, Life Technologies). Normalization of the validation set was performed on the U6 RNA. 
All RT reactions were run in an Opticon qRT-PCR Thermocycler (Bio-Rad). Comparative qRT-PCR 
was performed in triplicate, including no-template controls. miRNA levels were quantified using the 
MyiQ2 (Bio-Rad). Relative expression was calculated using the comparative Ct method. 
For gene expression analysis, RNA was retro-transcribed with AMV Reverse Transcriptase to obtain 
cDNAs, according to provider’s instruction (Promega). Absolute quantification of targets was 
evaluated by qRT-PCR, using SYBR Green dye-containing reaction buffer (Real SG Master Mix 5x, 
Experteam). Standard curves (10-fold dilution from 101
 
to 10-4
 
attomoles) were prepared for all the 
analyzed genes (TGFβR1, TGFβR2, TGFβR3, SASH1, SP1, KRT13, β-catenin, WNT4, WNT5a, 
JUP, FLG, HPV16 E6 and E7) and housekeeping genes (GAPDH, SDHA and POL2a). All the 
primers for gene expression analyses were purchased from Sigma-Aldrich and the table below reports 
all the primer sequences with the corresponding Gene Bank accession ID. Incorporation of the SYBR 
Green dye into the PCR products was monitored in real time PCR, using the MyiQ2 Two Color Real-
time PCR Detection System (Bio-Rad). Ct values were converted into attomoles and normalized 
expression was evaluated by using GAPDH, SDHA or POL2a as housekeeping genes.  
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Primer Sequence 5’ – 3’ Gene Bank Accession 
Human TGFβR1 For CATTTTTCCCAAGTGCCAGT NM_001306210.1 
Human TGFβR1 Rev ACACCCCTAAGCATGTGGAG “ 
Human TGFβR2 For CCATGTCTCACAGCCAGCTA NM_001024847.2 
Human TGFβR2 Rev CCAGGAGAAATAAGGGCACA “ 
Human TGFβR3 For CCAAGATGAATGGCACACAC NM_003243.4 
Human TGFβR3 Rev CCATCTGGCCAACCACTACT “ 
Human SASH1 For CTGTCACCCCCTCAGTGTTT NM_015278.3 
Human SASH1 Rev GAACAGGGTGGAGTCCGTTA “ 
Human Sp1 For GGTGCCTTTTCACAGGCTC NM_138473.2 
Human Sp1 Rev CATTGGGTGACTCAATTCTGCT “ 
Human KRT13 For GTCTTCAGCACCCAGAGGAG NM_153490.2 
Human KRT13 Rev TTCGAGAAAGGCAGGAAACT “ 
Human β-catenin For GAAACGGCTTTCAGTTGAGC NM_001904.3 
Human β-catenin Rev CTGGCCATATCCACCAGAGT “ 
Human WNT4 For GCTGTGACAGGACAGTCGAT NM_030761.4 
Human WNT4 Rev GCCTCATTGTTGTGGAGGTT “ 
Human WNT5A For GGGTGGGAACCAAGAAAAAT NM_003392.4 
Human WNT5A Rev TGGAACCTACCCATCCCATA “ 
Human JUP For GAAAAGCTGCTCTGGACCAC NM_002230.2 
Human JUP Rev GACGTTGACGTCATCCACAC “ 
Human FLG For GGCAAATCCTGAAGAATCCA NM_002016.1 
Human FLG Rev TGCTTTCTGTGCTTGTGTCC “ 
Human GAPDH For GAAGGTGAAGGTCGGAGTC NM_001289746.1 
Human GAPDH Rev GAAGATGGTGATGGGATTTC “ 
Human SDHA For AGAAGCCCTTTGAGGAGCA NM_004168.3 
Human SDHA Rev CGATTACGGGTCTATATTC “ 
Human POL2a For GCAAATTCACCAAGAGAGACG NM_000937.4 
Human POL2a Rev CACGTCGACAGGAACATCAG “ 
HPV16 E6 1 For ACAAACCGTTGTGTGATTTGTT  
HPV16 E6 1 Rev CAGTGGCTTTTGACAGTTAATACA  
HPV16 E6 2 For GCAAAGACATCTGGACAAAAAG  
HPV16 E6 2 Rev ACCGACCCCTTATATTATGGAATC  
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HPV16 E7 1 For GAACCGGACAGAGCCCATTA  
HPV16 E7 1 Rev ACACTTCGAACAAAAGGTTACA  
HPV16 E7 2 For TAACCTTTTGTTCGAAGTGTGA  
HPV16 E7 2 Rev TTTGTACGCACAACCGAAGC  
 
 
3.4.3 Protein extraction and Western Blot Analyses 
 For cellular protein lysates, cells were scraped on ice using cold Ripa lysis buffer (150 nM NaCl, 
50 mM Tris HCl pH 8, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with a 
protease inhibitor cocktail (CompleteTM, Roche), 1 mM Na3VO4 (Sigma), 100 mM NaF (Sigma) 
and 1 mM DTT (Sigma). Proteins were separated in 4-20% SDS-PAGE (Criterion Precast Gel, Bio-
Rad) and transferred to nitrocellulose membranes (GE Healthcare). Membranes were blocked with 
5% dried milk in TBS-0·1% Tween 20 or in Odyssey Blocking Buffer (LI-COR, Biosciences) and 
incubated at 4°C overnight with primary antibodies. 
Primary antibodies were from Cell Signaling (rabbit polyclonal Claudin-1 #4933, rabbit polyclonal 
SMAD2/3 #5678, rabbit monoclonal pS465-7 SMAD2 #3108, rabbit monoclonal β-Actin #8457), 
Abcam (mouse monoclonal SP1 #ab51513), Bethyl (rabbit polyclonal SASH1 #A302-265), Sigma 
(rabbit polyclonal KRT13 #SAB2104755, mouse monoclonal b-Tubulin #T8203), Transduction Lab 
(mouse monoclonal E-cadherin #610404), Santa Cruz (mouse monoclonal PARP-1 #sc8007, goat 
polyclonal Vinculin N19 #sc7649), Millipore (mouse monoclonal GRB2 MABS89, mouse 
monoclonal gH2AX JBW301 05-636). Membranes were washed in TBS-0·1% Tween20 and 
incubated 1 hour at RT with IR-conjugated (AlexaFluor680, Invitrogen or IRDye 800, Rockland) 
secondary antibodies for infrared detection (Odyssey Infrared Detection System, LI- COR) or with 
the appropriate horseradish peroxidase-conjugated secondary antibodies (GE Healthcare) for ECL 
detection (Clarity Western ECL Substrate, BioRad). Band quantification was performed using the 
Odyssey v1.2 software (LI- COR) or the QuantiONE software (Bio-Rad Laboratories). The Re-Blot 
Plus Strong Solution (Millipore) was used to strip the membranes, when reblotting was needed. 
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3.5 Xenograft growth in mouse flanks and treatments  
 
Primary tumors were established by subcutaneous injection of 2x106 FaDu cells bilaterally in the 
flanks of female athymic nude mice (Harlan, 6 weeks old). Growth of primary tumors was monitored 
by measuring tumor width (W) and length (L) and calculating tumor volume based on the formula 
(W2xL/2). When tumors reached a volume of 1000-1200 mm3, mice pre-anesthetized underwent 
surgery to remove the primary tumors. To evaluate the effect of SB-525334 (Sigma) and Mithramycin 
A (Sigma) on the formation of recurrences, the day before surgery, the animals were randomly 
divided into groups according to experimental design (3 mice/control group, 4 mice/treatment). The 
administration of the drugs was performed following a “peri-operative schedule”, i.e. mice received 
the treatments the day before, the same day and the day after surgery. Vehicle or Mithramycin A 1 
mg/kg, resuspended in DMSO, were administered intraperitoneally for three consecutive days, 
following the “peri-operative schedule”. Vehicle or SB525334, resuspended in PBS, were 
administered 15 mg/kg with oral gavages following the “peri-operative schedule”, and also three and 
six days after surgery. The appearance of local recurrence was monitored by macroscopic 
examination of mice over a period of 8 weeks. Unless tumor burden was incompatible with the well-
being of the animals, mice were sacrificed at the end of the experiment and pathologically examined 
for the presence of microscopic recurrences. In vivo experiment was carried out in strict accordance 
with the recommendations contained in the Guide for the Care and Use of Laboratory Animals of the 
CRO Aviano, National Cancer Institute, Italy. The project was reviewed and approved by the CRO 
Institutional Animal Care and Use Committee and conducted according to that committee’s 
guidelines. All mice were monitored twice a week and euthanized when required in accordance to 
the “AVMA guidelines on Euthanasia”. All efforts were made to minimize suffering. 
 
3.6 Statistical analyses   
All graphs and statistical analyses were performed using PRISM (version 6, GraphPad, Inc.) and R, 
SAS Software 9.2 and R for statistical analyses. In all experiments, differences were considered 
significant when p was <0.05. Statistical analyses included paired and un-paired t-tests, Mann-
Whitney un-paired t-test and Spearman correlation test, used as appropriate and as specified in each 
figure. Differences in miRNA expression between patients’ groups were evaluated by non-parametric 
Wilcoxon test (two groups) or Kruskal-Wallis test (three groups).  Correlation between Array and 
PCR quantification of miRNAs was evaluated through Spearman correlation coefficient.
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4.1 Identification of miRNAs differentially expressed in recurrent and non-recurrent HNSCC. 
 
Primary HNSCC fresh frozen surgical samples collected from 44 patients (Table 1) who experienced 
(n=11) or not (n=33) local recurrence within 2 years from the first surgery were analyzed by 
Nanostring™ technology for the expression of 746 human and 82 viral miRNAs.  
 
Table 1. Distribution of relapsed or not relapsed HNSCC patients of the discovery cohort.  
Table reports the mean level of miRNA expression according to selected covariates. The significant differences 
are shown in bold. Abbreviations: cN, clinical evaluation of node status; cT, clinical evaluation of tumour size. 
 
Statistical analyses of normalized miRNA expression demonstrated that 7 miRNAs were significantly 
different between the two groups (Table 2) of the Discovery Cohort. Validation of these data by qRT-
PCR analyses confirmed significant differences for miR-1, miR-133a, miR-150 and miR-9 between 
recurrent and non-recurrent HNSCC.  
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Table 2. qRT-PCR validation of miRNAs differentially expressed in HNSCC patients. The table reports 
qRT-PCR validation data of the differentially miRNAs expression among HNSCC who underwent selective 
surgery that experienced recurrence respect to those that had not. * Speraman correlation: satisfactory value 
>0.5. 
 
In particular, univariant significance testing confirmed that miRNA-9 was upregulated, while miR-1, 
miR-133a and miR-150 were downregulated in tumours from recurrent patients (Fig. 1). No 
significant associations were found between expression of these miRNAs and other clinical and 
biological variables of the tumours, including the presence of TP53 mutation and the positivity for 
HPV infection (Table 1 and 3). Accordingly, miR-9 upregulation and miR-1, miR-133a and miR-150 
downregulation in recurrent tumours was confirmed also when only TP53 mutant or HPV-negative 
cases were considered (Fig. 1). Bioinformatic validation by data reiteration confirmed the 
significance of this interaction (Fig. 2). Using the classifier testing, we calculated the Area Under the 
Curve (AUC) to estimate the ability of the four miRNAs, each one alone or in combination, to predict 
recurrence. Models 1-4, built using a Naïve Bayes or a Logistic Regression models, in which the 
classifier combines miR-133a with miR-150, with or without miRNA-9, achieved a high AUC (80-
81%), high sensitivity (82-88%) and low false positive rates (29-35%), which translated into 65-71% 
specificity (Fig. 2). Our analyses also suggested that the addition of miR-1 does little to improve the  
classification accuracy (Fig. 3A).  
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Figure 1. Validation of differentially expressed miRNAs in the Discovery Dataset.  
Dot plots show the normalized expression of miR-1, -9, -133a and -150 in samples from primary HNSCC from 
recurrent (red) and non-recurrent patients (black). Bars indicate the mean and the 95% confidence interval. In 
the left column dot plots show the normalized miRNA expression of all 44 HNSCC samples. In the central 
column only the TP53 mutated samples and in left column only the HPV-negative samples were included in 
the analyses. Statistical significance is reported in each graph and was calculated with Mann-Whitney test. 
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Table 3. Histological and clinical features of HNSCC patients included in the Discovery Set.  
Table reports all the different covariates analysed in HNSCC patients of the Discovery Cohort, including TP53 
mutations and HPV status. 
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Figure 2. Design of a recurrence prediction model in HNSCC based on miRNA expression using a 
bioinformatic approach.  
A/B. ROC curve prediction recurrence formation using miRNA-9, -133a and -150 data iteration applying the 
Naïve Bayes (A) or Logistic Regression (B) models. The AUC is 81.3% (Sensitivity 878% and Specificity 
75%) in A and 80.3% (Sensitivity 82% and Specificity 71%) in B. C/D. ROC curve prediction recurrences 
formation using miRNA-133a and -150 data iteration applying the Naïve Bayes (C) or Logistic Regression 
(D) model. The AUC is 81% (Sensitivity 88% and Specificity 65%) in C and 81% (Sensitivity 83% and 
Specificity 69%) in D.	 
 
These computational analyses are in accord with the notion that miR-1 and miR-133a belongs to the 
same cluster79 and, consequently, their expression highly correlates, as we observed in our samples 
set (Spearman correlation value r=0.9621 and p<0.0001). Correlation analyses also indicated that 
miRNA-133a expression directly correlates with miR-150 (Spearman correlation value r=0.2984 and 
p=0.049) and that miR-9 expression inversely correlates with both miRNA-133a (Spearman 
correlation value r=-0.1715, p=n.s.) and miR-150 (Spearman correlation value r=-0.4757 and 
p=0.0011).  
Accordingly, using the HNSCC TCGA dataset76 we confirmed that i) miR-1 and 133a expression 
strongly correlate (R= 0.79; p<0.0001); ii) miR-9 inversely correlates with both miR-1 (R= -0.27; 
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p<0.0001) and miR-133a (R= -0.34; p<0.0001) and iii) the expression of miR-1, -133a, -150 and -9 
classify patients at high risk of relapse (Fig. 3B). 
 
 
Figure 3. Differentially miRNA expressions stratified HNSCC TCGA dataset with diverse prognosis.  
A. Table reporting the predictive value of miRNA combination tested using Logistic Regression or the Naïve 
Bayes models. TPR=True Positive Value (Sensitivity); FPR= False Positive Ratio (Sensitivity); AUC=Area 
Under the Curve. Thr=Threshold. B. Kaplan–Meier curve evaluating progression-free survival of patients with 
HNSCC clustered on the basis of the expression of miR-1, -9, -133a, and -150. 
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4.2 Bioinformatic analyses identified miRNA targets involved in the regulation of cell plasticity. 
 
Confirmed targets of the identified 4-miRNAs impinge on EMT process. Specifically, miR-9, 
promotes EMT by targeting E-Cadherin80 and miR-1, -133 and -150, act as EMT suppressors by 
targeting SLUG81, SNAIL82 and ZEB183, respectively.  
Since EMT plays a pivotal role in HNSCC progression and recurrence formation13,84, we applied the 
miRNADIP71 and NAVIGaTOR73 bioinformatic tools to integrate miRNA-target predictions with 
experimentally determined proteins-protein interactions (PPIs) from I2D as described74,85, focusing 
on genes regulating EMT (Fig.4). 
 
 
 
Figure 4. Bioinformatic analysis of miR-1, -133a and -150 targets.  
Bioinformatic analyses, using Navigator portal, highlighted miR-1, -133a and -150 putative targets among 
genes known to be markers of EMT, up-regulated in HNSCC recurrent samples, down-regulated in non-
recurrent HNSCC or up-regualted in HNSCC tumors as evaluated using Reis et al and Pavón et al datasets. 
These analyses showed that miR-1, -133a and -150 collectively targets SP1, b-Catenin and TGFb pathways. 
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We first identified 16 possible common targets of miR-1, -133a and 150 (Fig. 5A). Then, we built an 
interaction network by integrating these analyses with the genes upregulated in HNSCC, as 
determined by the TCGA consortium. These analyses led us to the identification of SP1 as a common 
target of these 3 miRNAs (Fig. 5B). Refinement of these results, using two other available HNSCC 
datasets of coding gene signatures that could predict recurrences in HNSCC72,86, also identified SP1 
(Fig. 5C) together with other genes belonging to the TGFb and b-Catenin pathways, as potential 
targets of miR-1, -133a and -150 (Fig. 5C).  
 
 
 
 
Figure 5. Identification of miR-1, 133a and -150 putative targets.  
A. Venn diagram showing the number of miR-1, -133a, and -150 common potential targets, among the EMT 
genes, altered in HNSCC. B. Visualization of miR-1, -133a, and -150 and SP1 network in HNSCC. Direct 
interactions are shown by edges. Red-border triangles identify genes upregulated in recurrent HNSCC and 
black-border triangles identify genes upregulated in HNSCC primary tumours. C. List of miR-1, -133a, and -
150 targets belonging to the TGFb and WNT pathways. 
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A similar approach was used to screen the 1611 potential miR-9 targets. By intersecting these targets 
with genes associated with EMT negative regulators and HNSCC recurrence formation and/or 
patients’ survival, we defined a complex interaction network that highlighted potential targets altered 
in HNSCC (Fig. 6A). Further refinement of these analyses led to the identification of Plakoglobin 
(JUP1), SASH1, Keratin 13 (KRT13) and Filaggrin (FLG), as the genes with the highest probability 
to represent miRNA-9 targets in recurrent HNSCC (Fig. 6B). 
Pathway enrichment analyses using pathDIP75, to integrate miR-1, -133a, and -150 with miR-9 
networks, identified significantly enriched pathways (Supplementary Table S2 ref. Citron et al87). 
The most frequently occurring genes belonged to Signal Transduction (30 genes; p<0.05), EGFR1 
(29 genes; p=0.01), Immune System (29 genes; p<0.02), Integrin a6b4 (26 genes; p=0.001), TNFa 
(23 genes; p=0.05), Developmental Biology (22 genes; p=0.02), and TGFb Signaling (22 genes; 
p=0.04) pathways. Interestingly, four prognostic genes from the work of Reiss and collegues86, are 
predicted to be regulated by miR-9-5p and miR-150-5p (using an updated miRNADIP 3.0.1; http:// 
ophid.utoronto.ca/mirDIP)71. 
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Figure 6. Identification of miR-9 putative targets in HNSCC.  
A. Bioinformatic analyses, using pathDIP portal, highlighted miR-9 putative targets among genes known to 
be markers of EMT and altered in recurrent HNSCC. Direct interactions are shown by edges. Diamonds 
identify genes belonging to the pro-survival signature, hexagons are genes downregulated in recurrent tumors 
and circles represent genes upregulated in non-recurrent HNSCC as determined using the Pavón dataset. B. 
Venn diagram showing the number of miR-9 potential targets, among the anti-EMT genes and among the 
genes altered in HNSCC. 
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4.3 Experimental validation of identified miRNAs targets involved in the regulation of EMT. 
 
Overall these analyses suggested that the relative expression of miR-1, -133a, -150 and miR-9 could 
play a functional role in HNSCC progression possibly by regulating EMT.  
To experimentally validate miRNAs targets identified in silico, we screened a panel of HNSCC-
derived cell lines for endogenous miRNAs levels to choose the most appropriate in vitro model. 
Generally, all cell lines expressed low levels of miR-1, -133a and -150 and higher levels of miR-9 
(Fig.7A-B).  
Intriguingly, FaDu and SCC9 cells expressing highest level of miR-9, display low levels of SASH1, 
KRT13 and of the epithelial marker E-Cadherin (Fig.7A-B).  
 
 
Figure 7. Characterization of miRNAs expression and related putative targets in a panel of HNSCC 
cells. A. Graph showing the normalized expression of miR-1, -9, 133a and 150 in a panel of HNSCC cell lines. 
Data represent the mean (±S.D.) of 3 independent experiments performed in duplicate. B. Western blot analysis 
of the indicated proteins in a panel of HNSCC cells. Actin was used as loading control. 
 
First, we focused on the four most probable miR-9 targets, namely JUP1, SASH1, KRT13 and FLG 
(Fig. 6B). In both cell lines, miR-9 knock-down resulted in the upregulation of SASH1 and KRT13, 
but not of JUP1, and FLG mRNAs (Fig. 8A-B). The increased SASH1 and KRT13 expression was 
also confirmed at protein level (Fig. 8C-D). As expected from the literature88, the down-modulation 
of miR-9 leads to a strong abrogation of N-Cadherin protein expression, further supporting the 
involvement of miR-9 in the regulation of a EMT-like phenotype (Fig. 8D). In CAL27 cells, 
expressing low endogenous miR-9, its overexpression decreased mRNA and protein expression of 
both SASH1 and KRT13 (Fig. 8E-F).  
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Figure 8. In vitro validation of miR-9 putative targets.  
A/B. Graphs showing (from left to right) the normalized expression of SASH1, KRT13, JUP and FLG mRNA 
of both control and miR-9 knockdown respectively in SCC9 (A) and FaDu (B) cells. Data report the median 
value (±SD) of three independent experiments performed in duplicate. Statistical significance was calculated 
using Student t test. C. Western blot analysis of SASH1 and KRT13 protein expressions in control and miR-9 
knockdown SCC9 cells. Tubulin was used as loading control. D. Western blot analysis of SASH1, KRT13, 
Zo-1 and N-Cadherin protein expressions in control and miR-9 knockdown FaDu cells. Tubulin was used as 
loading control. E. Graphs showing the normalized expression of SASH1 mRNA in control and miR-9 over-
expressing CAL27 cells. Data report the median value (±SD) of three independent experiments performed in 
duplicate. Statistical significance was calculated using Student t test. F. Western blot analysis of SASH1 and 
KRT13 protein expressions in control and miR-9 over-expressing CAL27 cells. GRB2 was used as loading 
control. 
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As a proof of principle, we also tested whether miR-9 could directly regulate SASH1 expression 
acting on its 3’-UTR, that contains three seed sites for miR-9 (Fig. 9A). Luciferase assay in FaDu 
cells demonstrated that miRNA-9 knockdown significantly increased the luciferase activity when the 
first seed site (position 217-223) was tested (Fig. 9B). Overall, these data suggest that SASH1 (and 
likely KRT13) could represent reliable markers of miR-9 activity in HNSCC cells.  
 
 
Figure 9. Validation of putative miR-9 seed sites in the 3’-UTR of SASH1 gene.  
A. Schematic design of the pGL3-vectors used to test the potential miR-9 seed sites in the SASH1 3’-UTR 
regulatory region. A, B and C, indicates the 3 regions tested in the luciferase experiments shown in B. B. 
Graphs showing the normalized luciferase activity of pGL3-vectors shown in A and transfected in control or 
miR-9 knock-down FaDu cells. Data represent the median values (±S.D.) of three different experiments. 
Statistical significance is report in the graph and was calculated using Student t test. 
 
We next experimentally validated SP1 as common target of miR-1, miR-133a and miR-150. 
Overexpression of miR-1, miR-133a or miR-150 alone did not affect SP1 mRNA or protein 
expression in different HNSCC cell lines. However, the combined overexpression of two and, even 
better, of the three miRNAs together significantly reduced SP1, at both protein and mRNA levels 
(Fig. 10A-D).  
Expression data paralleled luciferase assay on SP1 3’-UTR, that contains one seed site for miR-1 and 
miR-133a and two seed sites for miR-150 (Fig. 10E). Each miRNA alone slightly reduced the 
luciferase activity of each construct (Fig. 10F), further supporting the possibility that the three 
miRNAs need to work together to reduce SP1 expression.  
Members of TGFb and b-Catenin pathways were also predicted targets of miR-1, miRNA-133a and 
miRNA-150. Among the predicted targets of miR-1, -133a and -150 (i.e. TGFb-R1, -R2 and -R3, 
WNT4, WNT5A and CTNN1B), the expression of WNT5A strongly decreased in cells 
overexpressing miR-133a (Fig.11A) while the expression of TGFb-R3 decreased following the 
combined overexpression of the three miRNAs (Fig.11B).  
From a functional point of view, we observed that combined inhibition of miR-9 and overexpression 
of miR-1, -133a and -150 (Fig.11C) up-regulated the epithelial marker E-Cadherin in FaDu cells 
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(Fig.11D), supporting the hypothesis that balanced expression of miR-9 and miR-1, miR-133a and 
miR-150 plays a functional role in HNSCC recurrence formation by modulating the EMT process.  
 
 
Figure 10. Combined expression of miR-1, -133a and -150 is necessary to down-regulate SP1.  
A. Western blot analysis of SP1 protein expression in UMSCC74b cells expressing combination of miR-1, -
133a, and -150, as indicated. B. Graph showing the normalized expression of SP1 mRNA in UMSCC74b cells 
transfected as in (A). Data report the median value (±SD) of three independent experiments performed in 
duplicate. Statistical significance was calculated using Student t test. C. Western blot analysis of SP1 and 
SMAD2/3 protein expressions in UMSCC1 cells transfected with miR-1, -133a and -150, as indicated. D. 
Western blot analysis of SP1 protein expression in FaDu cells transfected with miRNA-1, -133a and -150 
alone or in combination, as indicated. In A, C and D tubulin was used as loading control. E. Schematic design 
of the pGL3-vectors used to test the potential miR-1, -133a and -150 seed sites in the SP1 3’-UTR regulatory 
region. A, B, C and D indicates the 4 regions tested in the luciferase experiments shown in F. F. Graphs 
showing the normalized luciferase activity of pGL3-vectors shown in E transfected in 293T17. Data represent 
the median value (±S.D.) of three different experiments. Statistical significance is report in the graph and was 
calculated using Student t test. 
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Figure 11. Validation of putative miR-1, -133a and -150 putative targets.  
A. Graph showing the normalized expression of WNT5a in CAL27 cells expressing miR-1, - 133a and -150 
alone or in combination. B. Graph showing the normalized expression of TGFβ-R3 mRNA in CAL27 cells 
expressing miR-1, -133a and -150 alone or in combination. Data report the median value (±S.D.) of 3 
independent experiments performed in duplicate. Statistical significance is reported in each graph and was 
calculated using Student t-test. C. Graph reporting the normalized expression of miR-9, -1, -133a, -150 in 
FaDu cell line transfected with antimiRNA-9 or with miR-1, -133a and 150 or their combination, as indicated. 
Data represent the median value (±SEM) of one experiment performed in triplicate. D. Western Blot analysis 
of E-cadherin, SP1 and SASH1 protein expressions in FaDu cell line treated as in C. Ponceau staining of the 
membrane was used as loading control. 
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4.4 In vitro functional implication of miR-9 driven EMT  
 
High expression of miR-9 could modulate an EMT-like phenotype in SCC, both impinging on 
SASH1 and KRT13 levels, as we observed (Fig. 8), and triggering an up-regulation of N-Cadherin 
(Fig.8D), suggesting an important involvement of miR-9 in the regulation of tumorigenic and/or 
survival capabilities.  
Moreover, recently it has been demonstrated that in SCC a subpopulation of stem cells display 
increased miR-9 expression respect to the differentiate tumour cells88, this is of particular clinical 
interest since there is a close correlation between the presence of a non-proliferative niche of stem 
cell and resistance to both chemo or radio-therapy89,90, dependent on the context, even if the 
mechanisms involved are not completely understood.  
These observations prompted us to investigate whether high expression of miR-9 could be linked to 
survival advantage of tumour cells, both in basal condition and under the selective pressure of radio- 
or chemo-therapy. 
To verify the role of miR-9 in the promotion of cell survival and tumorigenic potential in HNSCC, 
we generate stable antimiR-9 FaDu and SCC9 cells. Down-modulation of miR-9 results in a dramatic 
decrease of clonogenic survival capability in 2D, both in FaDu and SCC9 cells (Fig. 12A). Moreover, 
when FaDu cells are embedded in 3D-inert matrix, in anchorage-independent assay, antimiR-9 cells 
display a reduced colony formation ability, both for number and size, respect to the control ones (Fig. 
12B). Consistently, when miR-9 is transiently up-regulated in CAL27 cells, it remarkably increased 
their clonogenic ability in 2D assay (Fig. 12C). 
Since it has been demonstrated that both EMT and stem “niche” correlate with radio- and/or chemo-
resistance89, we next investigated the implications of miR-9 knockdown in the standard care of 
HNSCC focusing our attention in particular on radiotherapy, the elective treatment for early and 
advanced patients, and on chemotherapy, testing both cisplatin and anti-EGFR targeted agents.  
To investigate the role of miR-9 in the response to γ-radiation, we irradiate control or antimiR-9 
expressing FaDu and SCC9 cells with ionizing radiation at 5-Gy high dose or 2-Gy, a low dose that 
more closely resemble the hypo-fractionated regimens in patients91, and evaluated cell survival 
fraction. As expected from the previous observation, the abrogation of miR-9, both in FaDu and SCC9 
cell lines, resulted in a strong decrease in survival fraction, especially when the highest dose was used 
(Fig. 14A-B).  
Since γ-radiation exerts its major effect inducing DNA damage, we analysed the expression of 
phosphorylation in Ser139 of H2AX (i.e. γH2AX), a very sensitive and well-established marker for 
DNA double-strand breaks (DSBs)92. Following radiation, high levels of DNA damage are often 
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associated with radio-sensitivity rather than -resistance93. Intriguingly, in FaDu miR-9 knock-down 
cells we observed in increased γH2AX expression, when cells are treated with 2 Gy and even better 
with 5 Gy dose of radiation (Fig. 14C-D), further supporting that inhibition of miR-9 is sufficient to 
mediate a γ-radiation sensitivity in HNSCC, eventually impinging on a radio-resistant niche 
population. It is also interesting to note that when miR-9 expression was inhibited we observed a 
strong down-modulation of SP1 (Fig. 14D), corroborating the hypothesis that a possible crosstalk 
exists between miR-9 and EMT pathway targeted by miR-1, 133a and -150. 
 
 
Figure 12. miR-9 promotes cell survival and tumorigenic potential in HNSCC cell lines.  
A. Left panel shows representative contrast-phase images of survival clonogenic assay on FaDu and SCC9 
cells, expressing or not miR-9. Right panel reports the colony number quantification of the indicated cell lines 
modified for the expression of miR-9 and allowed to grow for 10 days. B. Left panel reports colony 
quantification of soft agar assay performed with FaDu control or miR-9 knock-down cells allowed to grow for 
15 days. Right panel showed representative contrast-phase images. C. Left panel reports the colony number 
quantification of control or miR-9 over-expressing CAL27 cells allowed to grow for 10 days. Right panel 
shows representative contrast-phase images of survival clonogenic assay on CAL27 cells modified for miR-9 
expression. All the experiments were performed three times in triplicate and the graphs report the median 
values (±SD). Statistical analyses are reported in each graph and were calculated using Student t test. 
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Figure 13. In HNSCC cells miR-9 expression leads to a survival advantage after genotoxic γ-radiation. 
A/B. Graph reports the survival fraction of control or antimiR-9 FaDu (A) and SCC9 (B) cells subjected to 2 
Gy or 5 Gy γ-radiation and then plated in clonogenic assay. Data are expressed as a mean (±SD) of three 
independent experiments performed in triplicate. Statistical significance was calculated using Student t test 
and is reported in each graph. C. Western Blot analysis of γH2AX in lysates from control or antimiR-9 FaDu 
cells non-irradiated (NIR) or irradiated with 2 Gy and harvested after 1, 8 or 24 hours. GAPDH was used as 
loading control. D. Western Blot analysis of γH2AX and SP1 in lysates from control or antimiR-9 FaDu cells 
non-irradiated (NIR) or irradiated with 5 Gy and harvested after 1, 8 or 24 hours. Ponceau staining of the 
membrane was used as loading control. 
 
To investigate whether the silencing of miR-9 could modulate also chemo-resistance, we tested the 
sensitivity of FaDu and SCC9 antimiR-9 cells to incremental dose of cisplatin or EGFR-targeted 
compounds. We did not notice any differences in cell viability between control and antimiR-9 cells, 
both in SCC9 and FaDu, when treated with cisplatin (Fig. 14A-B). Whereas, when we tested different 
anti-EGFR agents, either small inhibitors that exert their activity without the contribution of immune 
system (i.e. Gefitib and Erlotinib) or monoclonal antibody, such as Cetuximab, we observed a 
significant decrease of IC50 in antimiR-9 FaDu cells respect to the control ones (Fig. 14C-E).  
These data strongly suggest that in advanced HNSCC, a relative abundant population of miR-9 
expressing cells is intrinsically resistant to the standard radio- and targeted-therapy, thus confirming 
the potential prognostic value of miR-9 expression and highlighting the urgency of a novel clinical 
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treatments for this group of patients, which received an unfaithful toxic treatment and that may benefit 
for a more accurate personalized therapy. 
 
 
Figure 14. miR-9 silencing sensitizes HNSCC cells to anti-EGFR targeted agents.  
A/B. Cisplatin (CDDP) dose-response curve of control or antimiR-9 FaDu (A) and SCC9 (B) cells expressed 
as percentage of viable cells with respect to untreated ones. Graphs report the percentage (±SD) of three 
independent experiments performed in triplicate. C/D. Cell viability of control or antimiR-9 FaDu cells treated 
with incremental dose of Gefitinib (C), Erlotinib (D) or Cetuximab (E) for 72 hours. Graphs report the 
percentage (±SD) of viable cells folded to untreated cells. Graphs report the statistical significance calculated 
using Student t test: *p<0.05, **p<0.01 and ***p<0.001. 
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4.5 In vivo validation of identified miRNAs targets involved in the regulation of EMT. 
 
To verify if the predicted targets of the 4 miRNAs were effectively differentially regulated in HNSCC 
samples, we tested by qRT-PCR the expression SP1, TGFb-R1, R2 and R3, WNT4 and WNT5A, 
CTNN1B, SASH1 and KRT13 in the 44 samples described in Table 1-3 and analyzed for the 
expression of miRNAs (Table 2).  
In line with in vitro results, we observed that miR-9 targets, SASH1 and KRT13, were both 
significantly downregulated in patients who experienced recurrence (Fig. 15A) and the expression of 
SASH1 correlated directly with KRT13 and inversely with miRNA-9 in primary HNSCC (Fig. 15B-
C). Among miR-1, -133a and -150 targets, only SP1 and TGFb-R1 were significantly upregulated in 
HNSCC samples from recurrent patients (Fig. 15D) and their expression directly correlated (Fig. 
15E). No differential expression was observed for TGFb-R2, and R3, WNT4, WNT5A and CTNN1B 
between patients with or without recurrence (Fig.16).  
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Figure 15. Expression of identified miRNA targets in primary HNSCC from recurrent and non-
recurrent patients.  
A. Dot plots showing the normalized expression of SASH1 (left) and KRT13 (right) mRNA, in samples from 
primary HNSCC from recurrent and non-recurrent patients. Bars indicate the mean and the 95% confidence 
interval. Statistical significance was calculated using the Mann–Whitney test. B/C. Dot plot showing the 
correlation of SASH1 and KRT13 (B) or SASH1 and miR-9 (C) mRNA expression in HNSCC samples 
described in A. Correlation value (r) and statistical significance (P) were calculated using the Spearman 
correlation test. D. Dot plots showing the normalized expression of SP1 (left) and TGFb-R1 (right) mRNA 
expressions in samples from primary and recurrent HNSCC samples. Bars indicate the mean and the 95% 
confidence interval. Statistical significance reported in the graph was calculated using the Mann–Whitney test. 
E. Dot plot showing the correlation of SP1 and TGFb-R1 mRNA expression in HNSCC samples as in A. 
Correlation value (r) and statistical significance (P) were calculated using the Spearman correlation test. 
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Figure 16. Expression of WNT/b-catenin and TGFb pathway members in primary HNSCC from 
recurrent and non-recurrent patients.   
From left to right: Dot plots showing the normalized mRNA expression of CTNNB1, WNT4, WNT5, TGFb-
R2 and TGFb-R3, putative targets of miR-1, 133a and -150, in samples from HNSCC patients who underwent 
or not loco-regional recurrences, reported in Tables 1 and 3. Bars indicate the mean and the 95% confidence 
interval. No significant differences have been calculated using the Mann-Whitney test. 
 
To validate our findings in an independent cohort, we collected 78 HNSCC samples in our Institutes 
(Table 4) and evaluated the expression of the 4 miRNAs, SASH1, KRT13, SP1 and TGFbR1. In 
accord with previous results, miRNAs expression did not correlate with any biological variable of 
HNSCC patients, including sex, age, cancer site, T and N stages (Table 4).  
The expression of SASH1 inversely correlated with miR-9 and directly correlated with KRT13 
(Fig.17A-B). An inverse, although not significant, correlation was noticeable between miR-1 or miR-
133a and SP1 expression, as expected from the in vitro results (Fig.17C-D).  
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Table 4. Median expression of the identified 4-miRNAs in the Validation Dataset according to the 
selected characteristics.  
Table shows the independent expression of the identified 4-miRNAs from the different covariates considered. 
Abbreviations: cN, clinical evaluation of node status; cT, clinical evaluation of tumour size. 
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Figure 17. Correlation analyses of miRNA putative targets in primary HNSCC included in the 
Validation Cohort.  
A/B. Correlation analyses between SASH1 and miR-9 (A) or KRT13 (B) expressions in HNSCC samples 
included in the validation set. C/D. Correlation analysis between SP1 and miR-1 (C) or miR-133a (D). All 
graphs report correlation value (r) and statistical significance (p) both calculated with non-parametric two-
tailed Spearman correlation test.  
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4.6 miRNAs’ targets predict prognosis in the TCGA HNSCC dataset. 
 
We hypothesized that the expression of SASH1, KRT13, SP1 and members of TGFb pathway could 
be used in HNSCC as readout of miRNA activity and tested the expression and the correlation of 
these genes with miR-9 and miR-1, -133a and -150, in the TCGA dataset.  
In accord with the data obtained using our discovery- and validation-cohorts, correlation analyses 
confirmed that SP1 positively correlated with miR-9 and inversely with miR-133a (Fig. 18A-B). 
Similar results were observed for SMAD2 and SMAD3 expressions, used as readouts of SP1 and 
TGFb pathway activity (Fig. 18C-H).  
 
Results 
	
55	
 
 
Figure 18. Prognostic significance of miRNA targets in the TCGA HNSCC dataset.  
A/B. Dot plots showing the mRNA expression and correlation of SP1 and miR-9 (A) or SP1 and miR-133a 
(B) in the HNSCC TCGA dataset. C/E. Correlation analyses between SMAD2 and miR-133a (C), SP1 (D) 
and miR-9 (E) mRNA expression in HNSCC samples included in the TCGA dataset. F/H. Correlation analyses 
between SMAD3 and miR-133a (F), SP1 (G) and miR-9 (H) mRNA expression in HNSCC samples included 
in the TCGA dataset. Each plot reports the correlation and statistical analyses calculated with nonparametric 
two-tailed Spearman correlation (r) and Statistical significance (p). 
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Moreover, SASH1 expression directly correlated with KRT13 (Fig. 19A) and both were higher in 
tumour-free cohort (Fig. 19B-C).  
Cluster analyses, using the expression of SASH1, KRT13, SP1, TGFbR1, TGFbR2, SMAD2 and 
SMAD3, divided the HNSCC patients included in the TCGA dataset in two groups: one with low 
expression of SP1 and members of TGFb pathway and high expression of KRT13 and SASH1 
(Cluster 1) and the other with the opposite gene expression profile (Cluster 2) (Fig. 20A). This 
clustering had prediction power, since patients included in Cluster 2 displayed worse relapse free 
survival than patients included in Cluster 1 (HR=2.01; 95% CI 1.1-3.8; p=0.01; Fig. 20B). 
 
 
 
Figure 19. Prognostic significance of miR-9 putative targets in the TCGA HNSCC dataset.  
A. Correlation analyses between SASH1 and KRT13 mRNA expressions in HNSCC samples included in the 
TCGA dataset. Correlation and statistical analyses were calculated with nonparametric two-tailed Spearman 
correlation (r). Statistical significance (p) is reported in each plot. B/C. Dot plot showing the expression of 
SASH1 (B) and KRT13 (C) mRNA in HNSCC samples included in the TCGA dataset and divided based on 
the presence (red dots) or absence (black dots) of tumor. 
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Figure 20. Expression of miRNA targets predict prognosis of HNSCC patients in the TCGA dataset.  
A. Cluster analyses of TGFb-R1, TGFb-R2, SP1, SMAD3, KRT13, and SASH1 in HNSCC samples included 
in the TCGA dataset. B. Kaplan–Meier curve evaluating progression free survival of patients with HNSCC 
divided based on the cluster analysis shown in A. HR, confidence interval (between brackets), and significance 
(P) were evaluated with the log-rank test using the survival package in R.  
 
4.7 Peri-surgical treatment with SP1 and TGFbR1 inhibitors prevents local relapse in a 
xenograft model of HNSCC. 
The above data suggested that SP1 and TGFb pathway together with miR-9 expression could act 
synergistically in the establishment of recurrence in HNSCC patients. To evaluate this possibility, we 
first tested the in vitro efficacy of Mithramycin A (MTA), a validated SP1 inhibitor, and of two 
different TGFb-R1 inhibitors (SB525334, SB52 and SB431542, SB43) on HNSCC cell survival. 
While MTA was highly active in decreasing HNSCC cell survival, in the nanomolar range, both SB52 
and SB43 did not significantly affect cell survival, when used up to 100 µM (Fig. 21A). Yet, in all 
tested cell lines SB52, used at the ineffective dose of 40 µM, reduced by the half the IC50 of MTA 
(Fig. 21A), suggesting that they could have synergistic effects. Accordingly, MTA used at the 
concentration of 20 nM effectively induced PARP1 cleavage (marker of apoptosis) only in 
combination with SB52 or SB43 (40 µM) in FaDu cells (Fig. 21B). 
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Figure 21. In vitro synergistic combination of SP1 and TGFb pathways blockage.  
A. Table reports the IC50 values of SB431542 (SB43), SB525334 (SB52), and Mithramycin A (MTA) alone 
or in combination with SB52 (40 mmol/L) or SB43 (40 mmol/L) in the indicated HNSCC cell lines. Significant 
difference (***, p < 0.0001) between the IC50 of MTA, in the presence or not of SB52 or SB43, was calculated 
with unpaired two-tailed Student t test. B. Western blot analysis evaluating the expression of SP1, SMAD2/3 
(readouts of MTA activity), p27 (readout of SB52/SB43 activity), and PARP-1 (cleaved form used as marker 
of apoptosis) in FaDu cells, treated for 24 hours with 20 nmol/L MTA, 40 mmol/L SB52 or SB43, or their 
combination, as indicated. Tubulin was used as loading control.  
 
Based on these results we tested if combined pharmacological inhibition of SP1 and TGFb pathways 
could restrain the formation of local recurrences in vivo, using a model of HNSCC recurrences and a 
peri-surgical treatment schedule (Fig. 22A). Mice were subcutaneously injected with FaDu cells and 
tumour mass allowed to grow up to ~1cm3. Mice were then randomly divided in four groups: 1) sham-
treated; 2) treated with MTA 1 mg/kg; 3) SB52 15 mg/kg; 4) the combination of MTA and SB52. All 
groups were treated for 3 consecutive days (day − 1, day 0 and day +1, with respect to surgery) and 
two more doses (day +3 and +6) only for SB52 treatment. Tumours were surgically removed at day 
0 and appearance of local recurrence was monitored over the subsequent 8 weeks of follow-up (Fig. 
22A). Pathological analyses of explanted tumours, evaluating the presence and the width of resection 
margins, demonstrated that no significant differences existed among the four groups in the extent of 
radical surgery (Fig. 22B) 
Explanted tumours (6 from controls and 8/group of treatment, respectively) were analysed for the 
expression of phosphorylated SMAD2 (pS465-7 SMAD2) (Fig. 22C-D) and SP1 levels (Fig. 22E), 
as readouts of SB52 and MTA activity, respectively. A single administration of SB52 and/or MTA 
(administered the day prior to surgery) significantly inhibited SMAD2 phosphorylation and SP1 
expression in the tumours (Fig. 22C-E), confirming the in vivo efficacy of these drugs.  
Control mice developed local recurrence in 50% of injected sites and MTA used alone did not 
significantly alter the rate of recurrence formation (4/8, 50%) (Fig. 22F). Interestingly, treatment with 
TGFb-R1 inhibitor, SB52, as single agent considerably increased local recurrence formation, with 
recurrence occurring in almost all cases (7/8, 90%) (Fig. 22F). However, the combination of SB52 + 
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MTA completely prevented recurrence formation (0/8, 0%) (p=0.005 in log-rank test; HR = 10.01; 
by comparing control- and MTA+SB treated-mice) (Fig. 22F), suggesting that peri-surgical treatment 
with MTA and SB52 was sufficient to efficiently suppress HNSCC recurrence in vivo.  
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Figure 22. In vivo inhibition of SP1 and TGFb pathway effectively reduces recurrence formation in mice. 
A. Schematic representation of the experimental workflow used for the evaluation of recurrence formation in 
mice xenografted with HNSCC cells. Tumor-bearing mice received treatments at day -1, day 0 and days +1, 
+3 and +6 with respect to the surgery (day 0), as indicated. Mice have been followed up to 8 weeks to monitor 
recurrence formation. Control mice were treated with vehicle alone. B. Graph reports the evaluation of surgical 
resection margins in explanted tumors, measured with an optical microscope equipped with an ocular 
micrometer. Tumor free margins varied from 0.3 to 1.6 mm. No significant differences were observed among 
the 4 groups of treatment. C. Western blot analysis of tumors explanted from mice treated as described in A 
showing the expression of pSMAD2 (S465/7) and SMAD2/3. GRB2 was used as loading control. D/E. Dot 
plot reporting the normalized expression of pSMAD2 (D) or SP1 mRNA (E) in tumours explanted at day 0, 
described in A. Each dot represents a primary tumor that received the one dose of vehicle (black) MTA 1 
mg/kg (red), SB52 15 mg/kg (blue), or their combination of MTA+SB52 (green). F. Disease-free survival of 
mice subjected to surgery to remove primary tumors (1-1,2 cm3) and then treated with vehicle (black line), 
MTA at 1 mg/kg (red line), SB52 15 mg/kg (blue line), or combination of MTA+SB52 (green line). Kaplan-
Meier test has been used to calculate the significance of combo-treatment respect to control and to SB52-
treated mice.  
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Loco-regional and distant relapses are frequent events in HNSCC patients, mainly due to the 
advanced disease stage at the diagnosis. The appearance of recurrence strongly influences patients’ 
outcome and represents a common and unfavorable prognostic event1,2,94.  
Independently from the etiological risk factors, advanced HNSCC represents a heterogeneous 
disease, resulting from the accumulation of several genes mutation, leading to the loss of function of 
important oncosuppressor (i.e. TP53) or to the oncogene amplification (i.e. EGFR, CCND1), genomic 
events linked to a poor prognosis5,16. Although many studies have been conducted to clarify the 
molecular mechanisms behind the development of local or distant metastasis, no clear molecular 
mediators of recurrence formation have been identified so far. In this context, it has been reported 
that TGFb pathway alteration, frequently occurring in the advanced stage, plays a pivotal role in the 
establishment of cell plasticity, eventually leading to a lethal-EMT43,46,95.  
Since, TGFb has a dual role both oncosuppressive in early tumour stage and oncogenic in the 
advanced stages, possibly triggering to local and distant relapse, many efforts have been made to 
translate into clinical practice TGFb inhibitors for advanced malignance96. Unfortunately, TGFb 
pathway abrogation has deleterious consequence in term of local relapse, mainly because it inhibits 
TGFb-mediated cell apoptosis and strongly increases cell proliferation and invasiveness, through a 
cell re-program MET46,97. 
Advanced HNSCC, not only displays high percentage of loco-regional or distant relapse, but also the 
worse response to standard care, even when highly toxic schedule is administered9,17. 
It is not surprising that the two main clinical challenges for this malignance are, one side, the 
validation of putative biomarker able to classify high-risk patients and, on the other side, the 
discovery of new potential druggable targets to personalized standard therapy to those subgroup of 
advanced HNSCC patients.  
This PhD project tackled these two unmet clinical needs and aimed to identify a microRNAs signature 
of loco-regional recurrence in patients with HNSCC.  
We started from the profiling of 44 HNSCC primary tumours for miRNAs expression and we showed 
that four miRNAs can identify patients with HNSCC at high risk of developing recurrence. 
Intriguingly these 4 miRNAs are deeply involved in the regulation of different “master EMT-genes” 
involved in the EMT process, both in fibrosis and in solid tumours, in particular in breast cancer.  
Using both bioinfarmatic approaches and wet lab techniques, we have linked the balanced activity of 
these miRNAs to the regulation of EMT, a process considered a critical step in the progression of 
HNSCC from a pre-invasive to a frankly invasive stage26,31. Thus, we identified two principal 
pathways regulated by the balanced expression of these 4 miRNAs that likely play a role in the 
regulation of HNSCC recurrence via the modulation of EMT, the SP1 and the TGFb pathways.  
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On one side, miR-1, miR-133a, and miR-150 synergistically acted to regulate SP1 and, possibly, 
TGFb signalling members, two pathways largely involved in cancer progression and EMT. However, 
miR-9 acted by increasing N-cadherin level, a well-known EMT marker30, and lowering the 
expression of SASH1 and KRT13, two known tumour suppressors with potential anti-EMT roles in 
HNSCC progression98–100. Using two independent HNSCC samples cohorts and the TCGA datasets, 
we confirmed the inverse correlation between the identified miRNAs and their targets' expression, 
thus validating the six-gene signature as a molecular readout of miRNAs activity.  
Since miRNAs are relatively stable molecules, in the clinic-pathological practise their expression can 
be easily detected directly in the tissue, through in situ hybridization (ISH) assay62,67. In this context, 
our finding supports the possibility that expression of miR-1, miR-9, miR-133a, and miR-150 could 
be estimated directly in primary HNSCC. Alternatively, through immunohistochemistry (IHC) 
analysis, miRNAs balanced activity could be estimated by the evaluation of their targets’ expression 
(i.e. SP1, TGFb pathway members, SASH1 and KRT13). 
In clinic-pathological routine it would be promising the evaluation, as a prognostic marker, of 
correlation expression between miRNAs and six-gene signature (readout of this balanced activity), 
more than the sole miRNA expression, to identify patients at high risk of developing recurrence, a 
subgroup that may benefit for a personalized therapy, avoiding unnecessary toxicity and overcoming 
possible resistance to standard care.  
From a biological point of view, it is interesting to note that we describe here two new targets of miR-
9, SASH1 and KRT13, both already linked to the regulation of cell motility and invasion98–100. 
Although the aim of this study was limited to the assessment of their role as potential readouts of high 
miR-9 activity in vivo, it will be worth testing if SASH1 and KRT13 may partially mediate the miR-
9-induced local relapse in HNSCC.  
Moreover, it has been recently demonstrated that miR-9, targeting E-Cadherin and g-Catenin 
respectively in breast cancer and SCC, directly promotes EMT and cancer stem cell phenotype80,88. 
In light of these literature data, we focused on the study of miR-9 role in the establishment of 
recurrence formation and/or therapy resistance in HNSCC. Our preliminary data clearly indicated 
that miR-9 expression, even if it did not affect cell proliferation (data not shown), is necessary for the 
maintenance of survival capabilities and resistance to g-radiation and EGFR-targeted therapy. 
Possibly, miR-9 expression could modulate this EMT phenotype also acting on SP1 level, since we 
demonstrated a strong correlation expression between miR-9 and SP1, both in vitro and in vivo 
(Figure 13D and 18A). Further experiments will be performed to investigate the molecular 
mechanism that orchestrates this phenotype and to dissect the role of miR-9 contribution also in vivo.  
Importantly, our data point to the simultaneous inhibition of SP1 and TGFb pathway by the concerted 
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action of three miRNAs, miR-1, miR-133a, and miR-150, as a possible mechanism to prevent disease 
relapse. At a first glance, our data do not fit in the current literature showing that, in mouse models, 
the inhibition of TGFb pathway combined with K-Ras activation is linked to the onset of SCC in the 
skin and in the oral mucosa47,88. However, increasing evidences clearly show that, depending on the 
stages of tumour progression, TGFb pathway can exert either pro- or anti-tumorigenic effects95,96. 
For instance, increased TGFb signalling, in benign tumours or during the course of cancer induction, 
selects for more aggressive cells and contributes to metastasis formation, in different models of 
HNSCC42. Our data in the mouse model, showing that TGFb-R1 inhibition could result in different 
outcomes, depending on the simultaneous inhibition of SP1 by MTA or not (Figure 22F), confirm the 
hypothesis that TGFb pathway could act as tumour suppressor or tumour promoter in a context-
dependent manner. In strict accord with our data, SP1 is required for TGFb-induced EMT in 
pancreatic cancer101, and SP1 and SMAD2 proteins have been reported to directly interact in different 
models102,103, supporting the possibility that SP1 and TGFb pathway may act together to drive EMT, 
local invasion and, eventually, recurrence formation in HNSCC. The experimental and in silico 
analyses performed on our and on TCGA samples support this possibility and point to the expression 
of miR-1, miR-133a, and miR-150 as possible switches of the TGFb activity.  
We are aware that our study has limitations that should be taken into account. The cohort of patients 
used as a discovery set contains a relatively small number of heterogeneous patients that received 
different post-surgery treatments. These variables could have an impact on the prognostic value of 
the miRNA signature and also prevented the possible evaluation of its independent prognostic role in 
multivariate analyses. Although we experimentally validated the correlation between miRNAs 
expression and their targets, we could not test the potential prognostic value of these miRNAs in a 
second independent cohort of samples for the absence of a precise follow-up in this group of patients.  
Furthermore, it is important to point out that we focused our bioinformatic analyses on the relation 
between miRNAs expression and EMT regulators, and this represents a possible limitation of our 
study, since other biological pathways are also significantly altered by the same miRNAs in HNSCC.  
In perspective, it will be important to verify if these four miRNAs and/or six genes signatures could 
be prospectively validated to identify patients at high risk of recurrence who may merit to be treated 
with specific targeted therapies.  
The significant synergistic activity of the combined inhibition of SP1 and TGFb-R1 and the critical 
role of miR-9 in promoting resistance to both radiotherapy and EGFR-targeted therapy, strongly 
suggest the urgency to translate our finding to the clinic, this is of potential immediate translational 
relevance, since both SP1 and TGFb inhibitors have been already tested in cancer patients. 
 	
65	
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
6. REFERENCES
References 
	
66	
1. Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of Cancer Incidence, Mortality, and 
Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in 
Different Geographic Regions of the World. J. Clin. Oncol. 24, 2137–2150 (2006). 
2. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. 
Cancer 127, 2893–2917 (2010). 
3. Cloos, J. et al. Genetic susceptibility to head and neck squamous cell carcinoma. JNCI J. Natl. 
Cancer Inst. 88, 530–535 (1996). 
4. Ang, K. K. et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. 
N. Engl. J. Med. 363, 24–35 (2010). 
5. Poeta, M. L. et al. TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and 
Neck. N. Engl. J. Med. 357, 2552–2561 (2007). 
6. Husain, H. et al. Nuclear epidermal growth factor receptor and p16 expression in head and neck 
squamous cell carcinoma. The Laryngoscope 122, 2762–2768 (2012). 
7. Smeets, S. J. et al. Genome-wide DNA copy number alterations in head and neck squamous cell 
carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25, 2558 
(2005). 
8. Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C. & Bosch, F. X. Involvement of intact 
HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed 
pRb cell cycle control. Oncogene 21, 1510 (2002). 
9. Leemans, C. R., Braakhuis, B. J. & Brakenhoff, R. H. The molecular biology of head and neck 
cancer. Nat. Rev. Cancer 11, 9–22 (2011). 
10. Vergeer, M. R. et al. Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity 
and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study 
Using a Standardized Follow-Up Program. Int. J. Radiat. Oncol. 74, 1–8 (2009). 
11. Hutchinson, L. Cetuximab or cisplatin in HNSCC? Nat. Rev. Clin. Oncol. 13, 66 (2015). 
12. Nör, C. et al. Cisplatin Induces Bmi-1 and Enhances the Stem Cell Fraction in Head and Neck 
Cancer. Neoplasia 16, 137-W8 (2014). 
13. Blanchard, P. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a 
comprehensive analysis by tumour site. Radiother. Oncol. 100, 33–40 (2011). 
14. Tabor, M. P. et al. Persistence of Genetically Altered Fields in Head and Neck Cancer Patients. 
Clin. Cancer Res. 7, 1523 (2001). 
15. Califano, J. et al. Genetic Progression Model for Head and Neck Cancer: Implications for Field 
Cancerization. Cancer Res. 56, 2488 (1996). 
References 
	
67	
16. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 
333, 1157–1160 (2011). 
17. Hammerman, P. S., Hayes, D. N. & Grandis, J. R. Therapeutic insights from genomic studies of 
head and neck squamous cell carcinomas. Cancer Discov. 5, 239–244 (2015). 
18. Hama, T. et al. Prognostic Significance of Epidermal Growth Factor Receptor Phosphorylation 
and Mutation in Head and Neck Squamous Cell Carcinoma. The Oncologist 14, 900–908 (2009). 
19. Khan, H. et al. Correlation between expressions of Cyclin-D1, EGFR and p53 with 
chemoradiation response in patients of locally advanced oral squamous cell carcinoma. BBA 
Clin. 3, 11–17 (2015). 
20. Moreira, J., Tobias, A., O’Brien, M. P. & Agulnik, M. Targeted Therapy in Head and Neck 
Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-
Targeted Therapy and Immunotherapies. Drugs 1–15 (2017). 
21. Magrini, S. M. et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally 
advanced head and neck cancer: a randomized phase II trial. J. Clin. Oncol. 34, 427–435 (2015). 
22. Huang, J., Zhang, J., Shi, C., Liu, L. & Wei, Y. Survival, recurrence and toxicity of HNSCC in 
comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. 
BMC Cancer 16, 689 (2016). 
23. Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck 
cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-
induced rash and survival. Lancet Oncol. 11, 21–28 (2010). 
24. Mehra, R., Cohen, R. B. & Burtness, B. A. The Role of Cetuximab for the Treatment of 
Squamous Cell Carcinoma of the Head and Neck. Clin. Adv. Hematol. Oncol. HO 6, 742–750 
(2008). 
25. Tsai, J. H. & Yang, J. Epithelial–mesenchymal plasticity in carcinoma metastasis. Genes Dev. 
27, 2192–2206 (2013). 
26. Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442 
(2002). 
27. Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 
1234850 (2013). 
28. Masuda, M. et al. Stat3 orchestrates tumor development and progression: the Achilles’ heel of 
head and neck cancers? Curr. Cancer Drug Targets 10, 117–126 (2010). 
29. Kojc, N. et al. Transcription factors Snail, Slug, Twist, and SIP1 in spindle cell carcinoma of 
the head and neck. Virchows Arch. 454, 549–555 (2009). 
References 
	
68	
30. Nguyen, P. T. et al. N-cadherin expression is correlated with metastasis of spindle cell 
carcinoma of head and neck region. J. Oral Pathol. Med. 40, 77–82 (2011). 
31. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial–mesenchymal 
transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006). 
32. Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. 
Nat. Med. 19, 1438 (2013). 
33. Haslehurst, A. M. et al. EMT transcription factors snail and slug directly contribute to cisplatin 
resistance in ovarian cancer. BMC Cancer 12, 91 (2012). 
34. Hsu, D. S.-S. et al. Regulation of excision repair cross-complementation group 1 by Snail 
contributes to cisplatin resistance in head and neck cancer. Clin. Cancer Res. 16, 4561–4571 
(2010). 
35. Ota, I. et al. Snail-induced EMT promotes cancer stem cell-like properties in head and neck 
cancer cells. Oncol. Rep. 35, 261–266 (2016). 
36. Kemler, R. et al. Stabilization of β-catenin in the mouse zygote leads to premature epithelial-
mesenchymal transition in the epiblast. Development 131, 5817–5824 (2004). 
37. Oloumi, A., McPhee, T. & Dedhar, S. Regulation of E-cadherin expression and β-catenin/Tcf 
transcriptional activity by the integrin-linked kinase. Biochim. Biophys. Acta BBA-Mol. Cell 
Res. 1691, 1–15 (2004). 
38. Islam, S., Carey, T. E., Wolf, G. T., Wheelock, M. J. & Johnson, K. R. Expression of N-cadherin 
by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted 
cell-cell adhesion. J. Cell Biol. 135, 1643–1654 (1996). 
39. Jolly, M. K. et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. 
Front. Oncol. 5, (2015). 
40. Chen, C., Zimmermann, M., Tinhofer, I., Kaufmann, A. M. & Albers, A. E. Epithelial-to-
mesenchymal transition and cancer stem (-like) cells in head and neck squamous cell carcinoma. 
Cancer Lett. 338, 47–56 (2013). 
41. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–
1564 (2011). 
42. Ikushima, H. & Miyazono, K. TGFβ signalling: a complex web in cancer progression. Nat. Rev. 
Cancer 10, 415 (2010). 
43. Inman, G. J. Switching TGFβ from a tumor suppressor to a tumor promoter. Genet. Cell. Mech. 
Oncog. 21, 93–99 (2011). 
44. David, C. J. et al. TGF-β Tumor Suppression through a Lethal EMT. Cell 164, 1015–1030 
(2016). 
References 
	
69	
45. Bian, Y. et al. Progressive tumor formation in mice with conditional deletion of TGF-β signaling 
in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 
69, 5918–5926 (2009). 
46. Honjo, Y. et al. TGFβ Receptor I Conditional Knockout Mice Develop Spontaneous Squamous 
Cell Carcinoma. Cell Cycle 6, 1360–1366 (2007). 
47. Bornstein, S. et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased 
genomic instability and inflammation. J. Clin. Invest. 119, 3408–3419 (2009). 
48. Izeradjene, K. et al. KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce 
mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 229–
243 (2007). 
49. Truty, M. J. & Urrutia, R. Basics of TGF-ß and Pancreatic Cancer. Pancreatology 7, 423–435 
(2007). 
50. Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228–234 (2009). 
51. Lee, Y., Jeon, K., Lee, J., Kim, S. & Kim, V. N. MicroRNA maturation: stepwise processing 
and subcellular localization. EMBO J. 21, 4663 (2002). 
52. Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051–4060 
(2004). 
53. Han, J. et al. Molecular Basis for the Recognition of Primary microRNAs by the Drosha-
DGCR8 Complex. Cell 125, 887–901 (2006). 
54. Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export of pre-
microRNAs and short hairpin RNAs. Genes Dev. 17, 3011–3016 (2003). 
55. Hutvágner, G. et al. A Cellular Function for the RNA-Interference Enzyme Dicer in the 
Maturation of the <em>let-7</em> Small Temporal RNA. Science 293, 834 (2001). 
56. Kawamata, T., Seitz, H. & Tomari, Y. Structural determinants of miRNAs for RISC loading and 
slicer-independent unwinding. Nat. Struct. Mol. Biol. 16, 953–960 (2009). 
57. Gregory, R. I. et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 
432, 235–240 (2004). 
58. Mulrane, L., McGee, S. F., Gallagher, W. M. & O’Connor, D. P. miRNA dysregulation in breast 
cancer. Cancer Res. 73, 6554–6562 (2013). 
59. Friedman, R. C., Farh, K. K.-H., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res. 19, 92–105 (2009). 
60. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, 
function and decay. Nat. Rev. Genet. 11, 597–610 (2010). 
References 
	
70	
61. Witwer, K. W. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. 
Chem. 61, 56–63 (2015). 
62. Iorio, M. V. & Croce, C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143–159 (2012). 
63. Zavadil, J., Narasimhan, M., Blumenberg, M. & Schneider, R. J. Transforming growth factor-β 
and microRNA: mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 185, 
157–161 (2007). 
64. Villanueva, A. et al. Dynamic epigenetic regulation of the microRNA-200 family mediates 
epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062 (2012). 
65. Avissar, M., Christensen, B. C., Kelsey, K. T. & Marsit, C. J. MicroRNA Expression Ratio Is 
Predictive of Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 15, 2850 (2009). 
66. Babu, J. M., Prathibha, R., Jijith, V. S., Hariharan, R. & Pillai, M. R. A miR-centric view of 
head and neck cancers. Biochim. Biophys. Acta BBA - Rev. Cancer 1816, 67–72 (2011). 
67. Jamali, Z. et al. MicroRNAs as prognostic molecular signatures in human head and neck 
squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 51, 321–331 
(2015). 
68. Corcoran, C. D., Senchaudhuri, P., Mehta, C. R. & Patel, N. R. Exact inference for categorical 
data. Encycl. Biostat. (2005). 
69. Hall, M. et al. The WEKA data mining software: an update. ACM SIGKDD Explor. Newsl. 11, 
10–18 (2009). 
70. Klement, W., Wilk, S., Michalowski, W. & Matwin, S. Classifying Severely Imbalanced Data. 
in Advances in Artificial Intelligence: 24th Canadian Conference on Artificial Intelligence, 
Canadian AI 2011, St. John’s, Canada, May 25-27, 2011. Proceedings (eds. Butz, C. & Lingras, 
P.) 258–264 (Springer Berlin Heidelberg, 2011). doi:10.1007/978-3-642-21043-3_31 
71. Shirdel, E. A., Xie, W., Mak, T. W. & Jurisica, I. NAViGaTing the Micronome – Using Multiple 
MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs. PLOS 
ONE 6, e17429 (2011). 
72. Pavón, M. A. et al. Gene expression signatures and molecular markers associated with clinical 
outcome in locally advanced head and neck carcinoma. Carcinogenesis 33, 1707–1716 (2012). 
73. Brown, K. R. et al. NAViGaTOR: network analysis, visualization and graphing Toronto. 
Bioinformatics 25, 3327–3329 (2009). 
74. Brown, K. R. & Jurisica, I. Unequal evolutionary conservation of human protein interactions in 
interologous networks. Genome Biol. 8, R95 (2007). 
References 
	
71	
75. Rahmati, S., Abovsky, M., Pastrello, C. & Jurisica, I. pathDIP: an annotated resource for known 
and predicted human gene-pathway associations and pathway enrichment analysis. Nucleic 
Acids Res. 45, D419–D426 (2017). 
76. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck 
squamous cell carcinomas. Nature 517, 576 (2015). 
77. Gao, J. et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the 
cBioPortal. Sci. Signal. 6, pl1 (2013). 
78. Aguirre-Gamboa, R. & Trevino, V. SurvMicro: assessment of miRNA-based prognostic 
signatures for cancer clinical outcomes by multivariate survival analysis. Bioinformatics 30, 
1630–1632 (2014). 
79. Chan, W.-C. et al. MetaMirClust: discovery of miRNA cluster patterns using a data-mining 
approach. Genomics 100, 141–148 (2012). 
80. Ma, L. et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer 
metastasis. Nat. Cell Biol. 12, 247 (2010). 
81. Liu, Y.-N. et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via 
Slug-independent mechanisms. Oncogene 32, 296 (2012). 
82. Muraoka, N. et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and 
silencing fibroblast signatures. EMBO J. 33, 1565–1581 (2014). 
83. Yokobori, T. et al. MiR-150 is associated with poor prognosis in esophageal squamous cell 
carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104, 48–54 (2013). 
84. Haddad, R. I. & Shin, D. M. Recent advances in head and neck cancer. N. Engl. J. Med. 359, 
1143–1154 (2008). 
85. Pastrello, C. et al. Visual Data Mining of Biological Networks: One Size Does Not Fit All. 
PLOS Comput. Biol. 9, e1002833 (2013). 
86. Reis, P. P. et al. A gene signature in histologically normal surgical margins is predictive of oral 
carcinoma recurrence. BMC Cancer 11, 437 (2011). 
87. Citron, F. et al. An Integrated Approach Identifies Mediators of Local Recurrence in Head and 
Neck Squamous Carcinoma. Clin. Cancer Res. 23, 3769 (2017). 
88. White, R. A. et al. Epithelial stem cell mutations that promote squamous cell carcinoma 
metastasis. J. Clin. Invest. 123, 4390–4404 (2013). 
89. Krause, M., Dubrovska, A., Linge, A. & Baumann, M. Cancer stem cells: Radioresistance, 
prediction of radiotherapy outcome and specific targets for combined treatments. Radiother. 
Cancer Present Future 109, 63–73 (2017). 
References 
	
72	
90. Abdullah, L. N. & Chow, E. K.-H. Mechanisms of chemoresistance in cancer stem cells. Clin. 
Transl. Med. 2, 3–3 (2013). 
91. Marcu, L. G. Altered fractionation in radiotherapy: From radiobiological rationale to therapeutic 
gain. Cancer Treat. Rev. 36, 606–614 
92. Sak, A. & Stuschke, M. Use of γH2AX and Other Biomarkers of Double-Strand Breaks During 
Radiotherapy. Harnessing DNA Repair Improve Radiother. Outcome 20, 223–231 (2010). 
93. Olive, P. L. Retention of γH2AX foci as an indication of lethal DNA damage. Radiother. Oncol. 
101, 18–23 
94. Michiels, S. et al. Surrogate endpoints for overall survival in locally advanced head and neck 
cancer: meta-analyses of individual patient data. Lancet Oncol. 10, 341–350 (2009). 
95. Glick, A. B. The Role of TGF Signaling in Squamous Cell Cancer: Lessons from Mouse Models. 
J. Skin Cancer 2012, (2012). 
96. Bierie, B. & Moses, H. L. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of 
cancer. Nat. Rev. Cancer 6, 506–520 (2006). 
97. Qiu, W., Schönleben, F., Li, X. & Su, G. H. Disruption of Transforming Growth Factor β-Smad 
Signaling Pathway in Head and Neck Squamous Cell Carcinoma as Evidenced by Mutations of 
SMAD2 and SMAD4(1). Cancer Lett. 245, 163–170 (2007). 
98. Zeller, C. et al. SASH1: a candidate tumor suppressor gene on chromosome 6q24. 3 is 
downregulated in breast cancer. Oncogene 22, 2972–2983 (2003). 
99. Sun, D. et al. SASH1 inhibits proliferation and invasion of thyroid cancer cells through 
PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol. 8, 12276–12283 (2015). 
100. Yanagawa, T. et al. Loss of cytokeratin 13 expression in squamous cell carcinoma of the tongue 
is a possible sign for local recurrence. J. Exp. Clin. Cancer Res. CR 26, 215–220 (2007). 
101. Jungert, K. et al. Sp1 Is Required for Transforming Growth Factor-β–Induced Mesenchymal 
Transition and Migration in Pancreatic Cancer Cells. Cancer Res. 67, 1563 (2007). 
102. Docagne, F. et al. Sp1 and Smad transcription factors co-operate to mediate TGF-β-dependent 
activation of amyloid-β precursor protein gene transcription. Biochem. J. 383, 393–399 (2004). 
103. Feng, X.-H., Lin, X. & Derynck, R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce 
p15(Ink4B) transcription in response to TGF-β. EMBO J. 19, 5178–5193 (2000). 
 	
73	
 
